MyD88: central relay station of Interleukin 1 signaling pathway by Li, Chunsheng
MYD88: CENTRAL RELAY STATION OF INTERLEUKIN 1 SIGNALING 
PATHWAY 
 
By 
 
Chunsheng Li 
 
Dissertation 
Submitted to the Faculty of the  
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of  
DOCTOR OF PHILOSOPHY 
in 
Microbiology and Immunology 
December, 2005 
Nashville, Tennessee 
Approved: 
Professor Derya Unutmaz 
Professor Jack J. Hawiger 
Professor Luc Van Kaer 
Professor Dean W. Ballard 
Professor Brian E. Wadzinski
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my wife  
Yi 
whom I love deeply 
ACKNOWLEDGEMENTS 
 
 
 
I wish to wholeheartedly thank my mentor Dr. Jacek Hawiger for allowing 
me to spend the past several years in his laboratory. Jacek not only provided me 
with his great guidance and support during my training, but he also served as a 
role model for how to be an excellent, successful scientist and an exceptional 
person. I am also grateful to the members of my dissertation committee (Dr. 
Derya Unutmaz, Dr. Dean Ballard, Dr. Luc Van Kaer, and Dr. Brian Wadzinski). 
Each of them provided me with guidance as well as with constant support and 
constructive criticism. I also want to thank the Department of Microbiology and 
Immunology for providing an environment where I could obtain an outstanding 
training and education, as well as good times outside of the laboratory. 
The research reported herein could not have been performed without the 
support of all of the lab members past and present. Dr. Danya Liu and Dr. Yan 
Liu are collaborators, friends, and family members that have always been helpful 
and supportive during this journey. I am indebted to Dr. Jozef Zienkiewicz, with 
whom I have the privilege to work on development of the computational models. 
I thank Dr Daniel Moore for critical reading of my thesis. I also want to thank the 
rest of the people in Hawiger`s laboratory (Daewoong, Jennifer, Ruth Ann, Ty 
and Chad) for their constant support and friendship.  
 iii
My parents have been the inspiration, the essential models for my life. My 
wife, Yi, has always been the best friend, best companion, and my one-woman 
cheer leader in the graduate school.  
The author’s work was supported by NIH Grants HL69542, HL62356, and 
HL68744. 
 
 iv
TABLE OF CONTENTS 
 
                     Page 
ACKNOWLEDGEMENTS……………………………………………………………………………..…iii 
LIST OF TABLES…………………………………………………………………..……………….……ix 
LIST OF FIGURES……………………………………………………………………………….……….x 
LIST OF ABBREVIATIONS……………………………………………………………………………xii 
Chapter 
I. BACKGROUND AND LITERATURE REVIEW……………………………………………1 
 
Cytokine-driven inflammation and diseases……………….……………………1 
Inflammation and inflammation-mediated diseases………………….1  
Inflammation is mediated by proinflammatory cytokines……….…2 
IL-1beta: a key cytokine in inflammatory response………………………….4 
IL-1 is a potent proinflammatory cytokine…………………………….4 
IL-1β production is regulated by the “inflammasome”…….……….5  
IL-1 is an important mediator in pathogenesis 
of multiple diseases…………………………………………………………….7  
IL-1β binds to IL-1R/IL1RAcP complex to induce  
downstream signaling pathway……………………………………………10 
Expanding IL-1 family members……………………….………………….14 
Receptors for IL-1β (IL-1R and IL1RAcP) are members 
of IL-1 receptor/TLR superfamily…………………………………………………14 
IL-1R and IL1RAcP contain Toll/interleukin 1 
 receptor (TIR) domain………………………………….……………………14 
Toll signaling pathway as the prototype of  
IL-1R/TLR signaling………………………………………………………….15 
IL-1R/TLR superfamily members can be  
divided into three families………………………..………………….………19 
IL1RAcP forms complex with IL-1R and recruits  
MyD88 via its TIR domain…………………………………………………...22
MyD88 is the central relay station for IL-1R/TLR  
signaling pathway………………………………………..……………………….……23 
MyD88 is the common adaptor protein in multiple  
IL-1R/TLRs signaling…………………………………………………………23 
 v
 
TIR-TIR interaction of MyD88 is an essential step  
in IL-1R/TLR signaling………………………………..……………………….24 
Other adaptor proteins are involved in IL-1R/TLRs signaling………..…27 
Formulation of working hypothesis and experimental strategy……..…31 
 
II. ANALYSIS OF MYD88 TIR DOMAIN IN IL-1Β PATHWAY……………….………33 
Synopsis………………………………………………………………………..………….33 
Introduction………………………………………………………………..…………….34 
Results………………………………………………………………………………………40 
Activation of NFκB by overexpression of MyD88  
and its death domain is abolished in Phe56Asn…………………….…41 
Structural characterization of MyD88 TIR domain…….....……..…47 
Box 3 of MyD88 TIR domain is involved in IL-1β 
-induced signaling………………………………………………..…………….48 
Site-directed mutagenesis of MyD88 TIR domain  
leads to loss of its inhibitory activity toward IL-1β 
-induced signaling ……….……………………………………..……………..53 
Inhibition of cytokine production by MyD88-TIR mutants…..…..59 
Mutagenesis of full-length MyD88 reveals an interactive  
site for direct contact with IL1RAcP……………………………………..63 
The development of the 3-dimentional docking model  
of MyD88-IL1RAcP interaction……………………………………………..66 
Homotypic oligomerization: interactive sites and  
docking model of MyD88 TIR domain……………………………………71 
Discussion……………………………………………………………………………...…74 
Summary and conclusions………………………………………………………..…76 
Future directions……………………………………………………………………..…80 
Comparative analysis of heterotypic interactions of 
MyD88 and TLRs……………………………………………………………..…80 
Developing cell-penetrating peptide/protein as  
therapeutic agents…………………………………………………………..…82 
 
  
III. GENE EXPRESSION PROFILING IN RESPONSE TO  
PROINFLAMMATORY AGONISTS …………………………………………...…………85 
 
Synopsis…………………………………………………………………..……………….85 
Gene expression profiling in response to  
staphylococcal enterotoxin B (SEB)………………………………………………86 
Systemic inflammation induced by staphylococcal  
enterotoxin B……………………………………………………..………………87 
 vi
  
cSN50 blocks the cytokine storm induced by  
superantigen SEB in vivo…………………………………………………..89 
Gene expression in the whole spleen correlates with  
SEB-induced toxic shock syndrome………………………..…………….93 
Gene expression in spleen T cells correlates with 
SEB-induced toxic shock syndrome………………………..…………….95 
Gene expression profiling in response to LPS ………..………………………98  
The role of Toll-like receptor 4 (TLR4) in LPS-induced  
inflammatory response in vivo………………………………..….………100  
The role of SRTFs in LPS-induced inflammatory  
response in vivo……………………………………………………..…….….103 
Discussion……………………………………………..…………………………………105 
Summary and conclusions…………………….……………………………………106 
 
  
IV. MATERIALS AND METHODS…………………………….………………………………108 
Cell lines…………………………………………….……………………………………108 
Plasmids and reagents………………………………………………………………108 
Generation of mutants………………………………………………………………109 
Transient transfection, reporter assay and cytokine   
cytometric beads array……………………..………………………………………112 
Immunoblotting and indirect immunofluorescence………….……………113 
Co-immunoprecipitation………………………………………….…………………114 
Modeling studies…………………………………………………………………….115 
Peptide synthesis……………………………………………………………………115 
Delivery of cell-penetrating peptides in vivo………..………………………116 
Measurement of cytokine/chemokine expression………..……………….116  
Isolation of T lymphocytes from the spleen………………..……………….117 
RNA extraction and reverse transcriptase reaction…………..………..…117 
Construction of microarray containing 22k genes ………..……………..118 
Target labeling and coupling ……………………………………..………….….119 
Data analysis of microarray …………………………………….….…………..120 
Affymetrix-based microarray analysis…………………….………….………122 
 
 
Appendix  
 
A.  INTERACTIVE SITES IN THE MYD88 TOLL/INTERLEUKIN  
(IL) 1 RECEPTOR DOMAIN RESPONSIBLE FOR COUPLING  
TO THE IL-1B SIGNALING PATHWAY…………………………………….…………123 
 vii
B. NUCLEAR IMPORT OF PROINFLAMMATORY TRANSCRIPTION  
FACTORS IS REQUIRED FOR MASSIVE LIVER APOPTOSIS  
INDUCED BY BACTERIAL LIPOPOLYSACCHARIDE…………..………...........132 
 
REFERENCES……………………………………………………………..……………………………142 
 viii
LIST OF TABLES 
 
 
 
Table                              Page 
 
1. Information about the MyD88 mutants analyzed in this study……..…………..64 
2. Oligonucleotides used for alanine substitution………………………….……………109 
 
 
 
 ix
LIST OF FIGURES 
 
 
 
Figure                    Page 
 
1. IL-1β signaling, expression and cleavage …………………………………..………….….6 
 
2. Neonatal-Onset Multisystem InflammatoryDisease (NOMID) ………………….…..9 
 
3. Toll signaling pathway in Drosophila as the prototype  
of mammalian IL1R/TLR signaling pathway. ……………………………………..……11 
 
4. MyD88 as the central relay station for multiple IL1R/TLR signaling 
pathways……………………………………………………………..………………………………16 
 
5. The members of the IL1R/TLR superfamily. ………………….……………………….20 
 
6. MyD88 contains TIR domain and death domain. …….…….………………………….25 
 
7. Schematic diagram of five members in the adaptor family  
of IL1R/TLR superfamily…………….…………….………...………………….…………….30 
 
8. Sequence alignment of the TIR domain of human MyD88 and TLR-2……….…37 
 
9. Structural model of the MyD88 TIR domain with conserved box 1-3…………..38 
 
10. NFκB-dependent reporter gene activation by overexpression  
of MyD88 and its mutants. ….…… …………….…………….……………….………….42 
 
11. Inhibition of IL1β-induced κB reporter gene activity by  
 MyD88 TIR domain..… ….………………….………….…………….……….………….…..49 
12. Selected MyD88 TIR domain mutants with “loss of inhibition”  
phenotype……………………………………………………………………….………………….54 
 
13. Functional analysis of MyD88 TIR domain mutants tested  
in κB reporter gene activity assays……….……………….…………….………….……57 
 
14. Inhibition of IL-6 production….………………….………….………….…….………….…60 
 
15. Interaction of MyD88 mutants with IL1RAcP………….…..…………….………..….65 
 
16. Sequence alignment of TIR domain of human IL1RAcP and TLR-1……..….…67 
 
 x
17. The 3-D models of TIR domain of IL1RAcP and MyD88,  
and the docking model of their TIR-TIR interaction. …………….……………….…68 
 
18. Homotypic interaction of the TIR domain of MyD88  
with full-length MyD88. ………….………….………….…………….………….……………73 
 
19. MyD88 TIR–TIR docking model………….……….…………….………….………………75 
 
20. Cytokine production and genome-wide expression profiling in  
the spleen induced by SEB and regulated by nuclear import  
inhibitor CSN50 or IκBαΔN transgene…………………………………………………..90 
 
21. SEB-induced gene expression profile in spleen T cells………….…………….……96 
 
22. TLR-4 mutation in C3H/HeJ mice render the LPS response in gene  
profiling compare with C3H/HeN mice………………………………..…………..……101 
 
23. Genome-wide expression profiling in the liver and spleen induced by  
LPS and regulated by nuclear import inhibitor CSN50……..……………………..104 
 
 
  
 
 
 
 xi
 
LIST OF ABBREVIATIONS 
 
AP-1    activation protein –1 
Caspase   apoptosis-related cysteine protease 
CBA    cytometric bead array 
DD    death domain 
DMEM   Dulbecco's Modified Eagle's Medium 
DN    dominant negative 
EDTA    ethylenediaminetetraacetic acid  
HEK    human embryonic kidney 
Ig    immunoglobulin 
IKK    I kappa B kinase 
IL    interleukin  
IL1RAcP   interleukin 1 receptor accessory protein  
IL1RI    interleukin 1 receptor I 
IRAK   interleukin 1 receptor–associated kinase 
JNK    c-Jun N-terminal kinase 
kDa    kilo Dalton 
LPS    lipopolysaccharide 
MAL    MyD88 adaptor-like protein 
MAP3K   mitogen–activated protein kinase kinase kinase 
Min    minutes 
 xii
MKK    MAP kinase kinase 
MyD88   myeloid differentiation primary response gene 88 
NFκB    nuclear factor kappa B 
NP-40    Nonidet P-40 
PAMP    pathogen–associated molecular patterns
PBS    phosphate-buffered saline
PCR    polymerase chain reaction 
PMSF    phenylmethylsulphonylfluoride 
PVDF    polyvinylidene fluoride 
RT    reverse transcription 
SARM    sterile alpha and TIR motif containing 
SDS    sodium dodecyl sulfate 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEB    staphylococcal enterotoxin B  
TAK    transforming growth factor(TGF) beta-activated kinase 
TICAM1   Toll-like receptor adaptor molecule 1  
TIR    Toll/interleukin 1 receptor  
TLR    Toll-like receptor 
TNF    tumor necrosis factor 
TRAF    TNF receptor-associated factor 
TRAM    TRIF-related adapter molecule 
TRIF    TIR domain containing adaptor inducing interferon-beta 
 xiii
CHAPTER I 
 
BACKGROUND AND LITERATURE REVIEW 
 
Cytokine-driven inflammation and diseases 
 
Inflammation and inflammation-mediated diseases 
In antiquity, the clinical features of inflammation were defined as rubor 
(redness), calor (warmth), tumor (swelling) and dolor (pain). These hallmarks of 
inflammation were first described about two thousand years ago by Celsus - 
Aulus (Aurelius) Cornelius, a Roman physician and medical writer. Now, 
inflammation is defined as a complex reaction of the innate immune system in 
vascularized tissues that involves the accumulation and activation of leukocytes 
and plasma proteins at the site of injury caused by infectious gents, chemical 
toxins, or trauma. Inflammation is initiated by changes in blood vessels that 
induce leukocyte recruitment. Local adaptive immune responses can promote 
inflammation as well. Although inflammation serves a protective function in 
controlling infections and promoting tissue repair, it can also cause “collateral” 
tissue damage and disease. 
Inflammation is the major mechanism of cardiac, pulmonary and vascular 
diseases mediated by leukocytes and plasma proteins. The inflammatory 
response underlies a variety of human diseases including atherosclerosis, 
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coronary and peripheral arterial disorders exemplified by Kawasaki disease and 
systemic lupus, acute and chronic lung diseases such as asthma, acute 
respiratory distress syndromes, and interstitial lung disease. Inflammation is also 
related to a variety of autoimmune diseases including type 1 diabetes, multiple 
sclerosis, and rheumatoid arthritis (Baugh and Bucala, 2001; Dinarello, 2002). 
Thus, understanding the mechanism underlying inflammation will help in 
development of effective therapies for these diseases. 
 
Inflammation is mediated by proinflammatory cytokines 
 Cytokines mediate major pathological processes including inflammation, 
angiogenesis, tissue remodeling, and fibrosis (Andreakos et al., 2004). The key 
cytokines involved in these processes are interleukin-1 (IL-1) and tumor necrosis 
factor-alpha (TNF-α) (Baugh and Bucala, 2001; Dinarello, 1996; Dinarello, 2000; 
Dinarello, 2002). Both of these cytokines are mediators for local inflammation by 
acting on vascular endothelium at the site of infection to induce the expression 
of adhesion molecules that promote migration of inflammatory and 
immunocompetent cells into the extravascular tissue compartment. In addition, 
large quantities of IL-1 and TNF-α in circulation are responsible for the systemic 
manifestations of infection by causing fever, producing hepatic acute phase 
plasma proteins, and initiating metabolic wasting (cachexia) (Roubenoff et al., 
1994).  A striking example of cytokine-induced systemic inflammation is septic 
shock, which is the most severe pathologic consequence of infection by gram-
2
negative and some gram-positive bacteria, characterized by circulatory collapse 
and disseminated intravascular coagulation (Hawiger, 1976). Thus, anti-cytokine 
therapy is a potential effective strategy for treatment of these diseases. 
To counteract the detrimental effect of these cytokines in inflammatory 
responses, therapeutic application of TNF-α neutralization with specific antibody 
and IL-1 blockade with a receptor antagonist have been developed. The latter, 
Anakinra, is the recombinant form of the naturally occurring IL-1 receptor 
antagonist (IL-1Ra) (Dinarello, 2004). Anakinra is successfully applied for 
treatment of autoinflammatory diseases due to excessive production of IL-1β 
(Hawkins et al., 2004; Hawkins et al., 2003; Hoffman et al., 2004; Lovell et al., 
2005).  Alternatively, specific blockade of the downstream signaling pathways of 
these cytokines can directly target the pathological processes without wide-
spread impairment of host defense mechanisms caused by using receptor 
antagonist or neutralizing antibody. To obtain more mechanistic insight assisting 
the development of specific therapeutic agents for IL-1-driven inflammation-
related diseases, my thesis studies focused on the molecular mechanism of an 
essential step in IL-1 mediated signaling, the interaction between the IL-1 
receptor and its downstream adaptor, myeloid differentiation primary response 
gene 88 (MyD88). 
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IL-1β: a key cytokine in inflammatory response 
 
IL-1β is a potent proinflammatory cytokine  
As one of the most potent proinflammatory cytokines, IL-1 plays an 
important role in inflammatory and immune responses. Its actions include the 
induction of fever, stimulation of the synthesis of hepatic acute phase reactants, 
upregulation of endothelial cell adhesion molecules, and stimulation of 
chemokine production by endothelial cells and macrophages (Auron et al., 1984; 
Dinarello, 1996). IL-1 was originally identified under a number of names 
corresponding to its different biological activities (endogenous pyrogen, 
lymphocyte activating factor, thymocyte proliferation factor, and catabolin, 
amongst others). 
 The role of the pleiotropic cytokine IL-1 in innate immune response to 
microbial pathogens is well established (Murphy et al., 2000). IL-1 is produced 
mainly by mononuclear phagocytes upon stimulation by pathogen - associated 
molecular patterns (PAMP), such as lipopolysaccharide (LPS), and by other 
cytokines, such as TNF-α (Liu et al., 2004a). IL-1 is also produced by many cell 
types other than activated macrophages such as peripheral neutrophilic 
granulocytes, endothelial cells, fibroblasts, Langerhans cells of the skin, microglia 
cells and many other cell types. Functional IL-1 agonist exists in two forms: IL-1α 
and IL-1β (Dinarello and Wolff, 1993). Each of these two forms is encoded by a 
separate gene as a 31 kDa precursor protein termed proIL-1α and proIL-1β, 
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which are proteolytically cleaved by calpain and caspase-1 (also named IL-1β 
converting enzyme, ICE), respectively (Kobayashi et al., 1990). IL-1α is localized 
either on the cell surface as well as in the cytoplasm, indicating IL-1α exerts its 
biological function in an autocrine manner. In sharp contrast, IL-1β is released 
from activated macrophages and transduces signal to other cells. Both agonists, 
IL-1α and IL-1β, bind to the same receptor complex and have identical biologic 
effects, although the majority of the circulating ligand for IL-1 receptor complex 
is IL-1β. IL-1Ra is another member of IL-1 family, produced by most cell types 
expressing IL-1 and binds to the same IL-1 receptor complex as a competitive 
antagonist (Arend et al., 1998).  Competition between IL-1β and IL-1Ra 
determines lymphocyte response to stimuli like phytohaemagglutin (Dabrowski et 
al., 2001).  
 
IL-1β production is regulated by the “inflammasome”  
As depicted in figure 1, upon activation by PAMP, macrophages are 
programmed to express IL-1β in a NFκB-dependent manner which will be 
described later in this chapter. IL-1β is synthesized as an inactive proIL-1β 
precursor, of which the proteolytic maturation is controlled by the cysteine 
protease caspase-1 (Thornberry et al., 1992). The latter itself is present in the 
cytosol as a 45 kDa precursor, which can be induced to undergo a series of 
processing events necessary for its activation. Although the mechanism of 
caspase-1 activation is still unclear, a multiprotein complex (termed the 
5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. IL-1β signaling, expression and cleavage 
IL-1β expression in macrophages is induced in a NFκB-mediated, MyD88-
dependent fashion. Initially synthesized as an inactive precursor, IL-1β is 
proteolytically processed into mature form by the cysteine protease, caspase-1, 
which originally exists as a 45kDa precursor in the cytosol and undergos a series 
of processing events for its activation. The activation of procaspase-1 is mediated 
by a multiprotein complex ("inflammasome"), which also consists of NALP-3 
(NACHT/LRR/pyrin domain-containing protein) and Asc (apoptosis-associated 
speck-like protein containing a CARD) (Martinon et al., 2002). NALP-3 belongs to 
the nucleotide-binding oligomerization domain protein family, which has been 
implicated recently in innate recognition of bacteria and the induction of 
inflammatory response. Asc is a caspase-recruitment domain (CARD) and pyrin 
domain containing protein, mediating the procaspase-1 oligomerization via 
binding to procaspase-1 by CARD-CARD interaction and to NALP-3 by pyrin-pyrin 
domain interaction (Srinivasula et al., 2002). 
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"inflammasome") that is involved in the activation of procaspase-1 upon LPS 
stimulation was identified recently (Martinon et al., 2002). The inflammasome 
consists of caspase-recruitment domain (CARD) and pyrin domain-containing 
proteins including Asc (apoptosis-associated speck-like protein containing a 
CARD), which mediate the oligomerization of procaspase-1 to facilitate its 
activation process (Srinivasula et al., 2002). The CARD of Asc binds the CARD of 
procaspase-1, whereas the pyrin domain of Asc can interact with the pyrin 
domain of NALP-3 (NACHT/LRR/pyrin domain-containing protein 3), a protein 
belonging to the nucleotide-binding oligomerization domain protein family, which 
has been implicated recently in innate recognition of bacteria and the induction 
of inflammatory responses (Mariathasan et al., 2004; Yu et al., 2005). 
 
IL-1 is an important mediator in pathogenesis of multiple diseases    
Production of functional IL-1β is process that is a tightly controlled by both 
its NFκB-mediated transcriptional activation and inflammasome-mediated 
proteolytic maturation. Apart from its role in orchestrating acute phase responses, 
IL-1β is an important mediator in the pathogenesis of many inflammatory and 
immunological mediated diseases. Unrestrained processing, release, and 
stimulation by IL-1β can be detrimental to the host. Abnormal IL-1β is related to 
many inflammatory diseases (Aksentijevich et al., 2002; Hawkins et al., 2004). A 
spectrum of diseases is related to abnormal inflammasome function. It ranges 
from Neonatal-Onset Multisystem Inflammatory Disease (NOMID, also known as 
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chronic infantile neurologic, cutaneous, articular [CINCA] syndrome) to Muckle-
Wells syndrome to familial cold autoinflammatory syndrome (Aksentijevich et al., 
2002; Hawkins et al., 2004; Hoffman et al., 2001). NOMID and Muckle-Wells 
Syndrome are closely associated with germline mutations in NALP-3 
(Aksentijevich et al., 2002). As exemplified by NOMID, these autoinflammatory 
diseases are characterized by fever, chronic meningitis, uveitis, sensorineural 
hearing loss, urticaria, and a characteristic deforming arthropathy (figure 2). 
Recently, antagonist therapy with the recombinant form of IL-1Ra (Anakinra) has 
been shown to be effective to alleviate these symptoms (Dinarello, 2004).  
The overproduction of IL-1β, orchestrated by TNF-α, drives 
pathophysiological processes that lead to the clinical symptoms of rheumatoid 
arthritis (RA) (Schiff, 2000). IL-1β has been implicated in a number of other 
chronic inflammatory or autoimmune diseases including diabetes, graft-versus-
host disease, inflammatory bowel disease, various allergic skin diseases, and 
asthma (Rosenwasser, 1998). IL-1β also mediates systemic host defense 
responses to pathogens and to injury within the central nervous system (CNS) 
(Basu et al., 2004; Basu et al., 2005) . Polymorphisms in the IL-1β locus in 
patients have been associated with increased IL-1β levels in the brain and are 
considered one of the indicators for higher risk of Alzheimer disease (Mrak and 
Griffin, 2001). IL-1 has trophic effects on hematopoietic lineages and has been 
implicated in both the promotion and suppression of hematopoietic malignancies 
as well as some solid malignancies. In addition, in vivo angiogenesis and 
8
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Figure 2. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) 
Clinical features of neonatal-onset multisystem inflammatory disease/chronic 
infantile neurologic, cutaneous, and articular (NOMID/CINCA) syndrome. Top left, 
facial features. Top middle, urticarial rash, which persisted throughout a week-
long hospital visit. Top right, contractures of the knees. Bottom left, funduscopic 
image, demonstrating papilledema in the left eye (present bilaterally). Bottom 
middle, skin biopsy sample, showing a mild perivascular leukocytic infiltrate, with 
some eosinophils but no epidermal changes. Bottom right, magnetic resonance 
image of the right knee, demonstrating the absence of significant synovial 
enhancement and the presence of epiphyseal and patellar bony overgrowth.  
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invasiveness of different tumor cells require the production of IL-1 (Voronov et 
al., 2003). Therefore, better understanding of IL-1 signaling may reveal possible 
therapeutic targets in cancer, Alzheimer’s disease, in addition to 
autoinflammatory and chronic autoimmune disease such as rheumatoid arthritis. 
 
IL-1β binds to IL-1R/IL-1RAcP complex to induce downstream signaling pathway 
 
Two different membrane receptors for IL-1β have been characterized, 
namely IL-1RI and IL-1RII. They are transmembrane proteins with three 
extracellular immunoglobulin-like domains.  Although both the IL-1RI and IL-1RII 
are immunoglobulin superfamily members, their biological function and 
expression pattern are quite different. Unlike IL-1RII, which is only expressed on 
B lymphocytes and exerts its function as a decoy to competitively inhibit IL-1 
signaling, IL-1RI is expressed on the cell surface of most cell types and is the 
functional receptor for IL-1 signaling.  
The crystal structure of  IL-1R/IL-1β complex suggested that IL-1β is 
wrapped in three immunoglobulin domains of  IL-1R (Vigers et al., 1997). The 
interaction between IL-1 and its receptor is enhanced by involvement of other 
immunoglobulin superfamily members. IL-1β exerts its function by binding to its 
cognate receptor complex, formed by two extracellular-immunoglobulin 
containing proteins, IL-1RI and IL-1 receptor accessory protein (IL1RAcP). 
IL1RAcP was identified as an essential component in the receptor complex 
(Greenfeder et al., 1995; Wesche et al., 1997b). As shown in figure 3, via 
10
  
 
 
 
 
 
Figure 3. Toll signaling pathway in Drosophila as the prototype 
of mammalian IL1R/TLR signaling pathway.  
A, Comparison of the Toll signaling pathway in Drosophila and 
mammalian IL1R/TLR signaling pathway. In Drosophila, activation of the 
cell surface receptor Toll by the extracellular ligand Spaetzle lead to 
formation of trimeric complex of dMyD88, Tube and Pelle. Activated 
kinase Pelle exerts its function by phosphorylation and degradation of 
IκB-like inhibitor molecule Cactus, in turn activates the nuclear 
translocation of NFκB-like molecule Dorsal, which regulates 
transcriptional activation of multiple gene including Drosomysin. Three 
intermediate signal transducers are required for Dorsal activation via Toll: 
IRAK-related Pelle, drosophila MyD88, and MAL/TIRAP homolog Tube. 
The essential receptors and transducers of this pathway are conserved in 
mammals. See the text for details.  
B, The IL-1 signaling pathway in mammals. P: phosphorylation; Ub: 
Lys63-mediated polyubiquitination. See the text for details and 
references.  
11
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binding to its cognate receptor complex IL-1β activates specific protein kinases, 
including the NFκB inducing kinase (NIK) and three distinct mitogen-activated 
protein (MAP) kinase cascades (Dinarello, 1996). These signal transducers 
mobilize transcription factors, including nuclear factor kappa-B (NFκB), activator 
protein – 1 (AP-1) and cyclic AMP (cAMP) element binding protein (CREB). In 
turn, these transcription factors initiate the synthesis of a plethora of immediate 
early genes essential to the inflammatory response (Dinarello, 1996). Importantly, 
IL-1β induces genes that encode other mediators of inflammation such as 
inflammatory cytokine IL-6, TNF, interferons and chemokine macrophage 
inflammatory protein-1 (MIP1). IL-1 also activate cyclooxygenase type 2 (COX-2), 
type 2 phospholipase A and inducible nitric oxide synthase (iNOS), which account 
for the large amount of prostaglandin-E2 (PGE2), platelet activating factor and 
nitric oxide (NO) produced by stimulation both in vitro and in vivo. Additionally, 
IL-1 increases the expression of cell adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) on mesenchymal cells and vascular-cell adhesion 
molecule-1 (VCAM-1) on endothelial cells to promote the infiltration of 
inflammatory and immunocompetent cells into the extravascular space. IL-1 is 
also act as an angiogenic factor by increasing the expression of vascular 
endothelial growth factor (Akira and Sato, 2003; Dinarello, 1996; Dinarello, 2002; 
Vannier and Dinarello, 1994; Yamamoto et al., 2004). 
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Expanding IL-1 family members   
New molecules similar to IL-1 were identified recently based on both 
sequence homology and the presence of key structural motifs. For example, IL-
18 is classified as an IL-1 family member (i.e., IL-1γ), which is predicted to fold 
as a β-rich trefoil, the typical structure for IL-1 ligands. Moreover, IL-18 has 
similar characteristics of processing, receptor usage, and signaling. (Bazan et al., 
1996; Ghayur et al., 1997; Gu et al., 1997; Kojima et al., 1998; Tsuji-Takayama 
et al., 1999) . In addition, novel IL-1 ligands with high level of structural 
similarities to IL-1Ra have been identified (Barton et al., 2000; Busfield et al., 
2000; Kumar et al., 2000; Mulero et al., 1999; Pan et al., 2001; Smith et al., 
2000). IL-1δ, for example, specifically inhibits IL-1ε induced activation of NFκB 
through the orphan IL-1R-related protein 2 (IL-1Rrp2) (Debets et al., 2001). 
Interestingly, the majority of the IL-1 like proteins (i.e., IL-1Ra and other IL-1Ra-
like ligands) are clustered on long arm of human chromosome 2, just like IL-1β 
and IL-1α (Webb et al., 1986), suggesting a potential functional relevance of the 
encoded products within this gene cluster.  
 
Receptors for IL-1β (IL-1R and IL1RAcP) are members of IL-1 
receptor/TLR superfamily 
 
IL-1R and IL1RAcP contain Toll/interleukin 1 receptor (TIR) domain 
The signals generated by IL-1β binding to its cognate receptor complex, 
formed by two type-I transmembrane proteins, IL-1 receptor I (IL-1RI) and IL-
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1R accessory protein (IL1RAcP), are transduced by their cytoplasmic segments 
denoted as Toll/interleukin 1 receptor (TIR) domain. The TIR domain is about 
150-180 amino acids in length and essential for signal transduction via protein-
protein interactions. The TIR domain is conserved in Drosophila Toll, mammalian 
Toll-like receptors (TLRs), and cytoplasmic adaptors, which are exemplified by a 
protein named MyD88. These molecules belong to the IL-1 receptor/TLR 
superfamily (McGettrick and O'Neill, 2004). All members of this superfamily 
mediate inflammation-related signaling in a similar pattern since they all contain 
the TIR domains, through which the stress-activated protein kinases, IKK, JNK, 
and P38, and the transcription factor, NFκB, are eventually activated (figure 4).  
 
Toll signaling pathway as the prototype of IL-1R/TLR signaling  
The Toll signaling pathway in Drosophila melanogaster is the prototypical 
example of signaling by the members of the Toll/IL-1 receptor superfamily. The 
Toll-mediated pathway is required for activation of Drosomycin, an antifungal 
peptide in response to microbial challenge (Lemaitre et al., 1996). As shown in 
figure 3A, activation of the cell surface receptor Toll by the extracellular ligand 
Spaetzle leads to phosphorylation and degradation of an IκB-like inhibitor 
molecule, Cactus. The removal of Cactus allows the nuclear translocation of 
NFκB-like molecule Dorsal, which regulates transcriptional activation of multiple 
genes including Drosomysin. Three intermediate signal transducers are required 
for Dorsal activation via Pelle (related to Toll/IL-1R-associated kinase, IRAK), 
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Figure 4.  MyD88 as the central relay station for multiple IL1R/TLR 
signaling pathways. MyD88 integrates signals flowing from IL1R/IL1RAcP 
complex and from an array of other TLRs except TLR-3. Upon activation of 
IL1R/TLRs by its ligand, MyD88 recruits IRAK and in turn TRAF6 that ultimately 
leads to activation of NFκB, P38 and JNK. The TLR-3 signaling pathway uses 
MyD88-indepednet pathway, in which adaptor proteins TRIF and TRAM are 
recruited to TLR-3 to activate IRF3 and lead to activation of interferon production. 
TRIF also activates TRAF6 and leads to NFκB activation. Function of SARM is not 
identified yet. 
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drosophila MyD88, and Tube (Lemaitre et al., 1996; Tauszig-Delamasure et al., 
2002). Drosophila MyD88 is required for the response to fungal and Gram-
positive bacterial infections (Tauszig-Delamasure et al., 2002).  
Similar to this ancestral signaling pathway, mammalian cells use these 
highly conserved intermediate components during IL-1 mediated signaling. 
MyD88 is the main adaptor protein which integrates signals flowing from multiple 
TIR domain containing receptors, including IL-1 receptor/IL1RAcP and most Toll-
like receptors with the notable exception of TLR-3 (Akira, 2003; McGettrick and 
O'Neill, 2004). As depicted in figure 3B, a family of related kinases, the IRAKs, 
plays a critical role downstream of MyD88. The first member of this family, IRAK-
1, is recruited to the receptor independently of MyD88. By contrast, IRAK-4 is 
recruited to the receptor through binding of MyD88. Once bound to the receptor 
complex, IRAK-1 becomes phosphorylated by IRAK-4 and subsequently 
autophosphorylated (Imler and Zheng, 2004). As a result, the kinases dissociate 
from the receptor complex and interact with the downstream component TNF 
receptor-associated factor 6 (TRAF6). Genetic evidence indicates that IRAK-4 
plays an essential role in the activation of this pathway, as responses to IL-1 are 
abolished in IRAK-4 knockout mice (Suzuki et al., 2002). By contrast, other 
kinases, possibly IRAK-2, can substitute for IRAK-1 since activation of TRAF6 is 
only attenuated in IRAK-1 deficient cells (Swantek et al., 2000). Another member 
of the family, IRAK-M, is a negative regulator of the pathway since IRAK-M 
mutant cells show exacerbated responses to TLR agonists (Kobayashi et al., 
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2002). Significantly, TRAF6 activates a heterodimer composed of two 
ubiquitination proteins called Uev1A and Ubc13 (Deng et al., 2000). Unlike the 
classical ubiquitination in which ubiquitin chains extending on Lysine 48 and 
leading to degradation of the modified protein by the proteasome, upon 
activation of TRAF6, noncanonical ubiquitin chains are extended on Lysine 63 , 
which trigger association with the MAP3 kinase TAK1  (transforming growth 
factor-β-activated kinase 1) (Silverman and Maniatis, 2001). Activated TAK1 
directly phosphorylates and activates the kinases IKKß (Inhibitor of kappa light 
polypeptide gene enhancer in B-cells kinase β) and MKK6 (MAP kinase kinase 6).  
IKKß is part of a large protein complex named signalsome (Mercurio et al., 
1997). This signaling complex also contains the regulatory component 
IKKγ/NEMO. IKKß phosphorylates the NFκB cytoplasmic inhibitor IκB. After IκB 
polyubiquitination and degradation by 26S proteosomes, NFκB is released and 
translocated to the nucleus where it activates transcription of multiple target 
genes that contain the kappa B element in their promoter regions. MKK6 
phosphorylates the c-Jun amino-terminal kinase (JNK) and leads to activation of 
another stress-responsive transcription factor, activator protein-1 (AP-1) 
(Silverman and Maniatis, 2001). AP-1 and NFκB activate transcription of genes 
that encode mediators and suppressors of inflammation (cytokines, chemokines, 
iNOS, adhesion molecules, etc), as well as costimulatory molecules such as CD40, 
CD80 and CD86 involved in adaptive immune response. 
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IL-1R/TLR superfamily members can be divided into three families  
The IL-1 receptor/TLR superfamily can be divided into three families 
(Dunne and O'Neill, 2003). Members of the first family contain one or three 
extracellular immunoglobulin (Ig) domains exampled by IL-1RI (figure 5). The 
second family is characterized by extracellular leucine-rich repeats (LRR) instead 
of immunoglobulin domains and comprises the Toll-like receptors (TLRs) family. 
TLRs are the mainstay of innate immunity and at least 10 members of the TLR 
family have been identified. TLRs recognize PAMPs on the surface of multiple 
pathogenic microorganisms. They also interact with CpG DNA and viral double 
stranded RNA. Upon ligand binding, TLRs induce production of inflammatory 
cytokines, chemokines, anti-microbial compounds, and costimulatory molecules, 
which subsequently participate in the adaptive immune response. Their 
expression depends on signaling to the nucleus mediated by NFκB, AP-1 and 
other stress-responsive transcription factors (SRTFs) (Hawiger, 2001). The third 
family consists of adaptor proteins, including MyD88, MyD88 adaptor-like 
(MAL/TIRAP), TIR domain−containing adaptor inducing interferon-β 
(TRIF/TICAM-1), TRIF-related adaptor molecule (TRAM) and sterile alpha and 
HEAT/Armadillo motifs (SARM) (O'Neill et al., 2003).  These TIR-containing 
adaptors are recruited to the TIR domains of the receptors and initiate signal 
transduction by activating IRAKs and the adaptor molecule TRAF6, consequently 
leading to the activation of signal transducers which mobilize SRTFs for nuclear 
translocation. Different signaling pathways may use different adaptors 
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Figure 5. The members of the IL1R/TLR superfamily. Mammalian, 
Drosophila, plant, and Xenopus proteins are shown in blue, red, green, and 
magenta, respectively. The superfamily can be divided into three families. Family 
1, the Ig family, all contain extracellular Ig domains and include receptors and 
accessory proteins for IL-1 and IL-18. Family 2, the LRR family, includes the 
signaling receptors for LPS (TLR-4) and molecules from Gram-positive bacteria 
such as peptidoglycan and lipoproteins (TLR-2). The adaptor family contains 
MyD88, MAL, TRIF, TRAM and SARM. Three superfamily members in 
Caenorhabditis elegans are not shown. 
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determining some specificity of signaling outcome from different receptors. While 
almost all the receptors recruit adaptor protein MyD88, some receptors can 
recruit other adaptors. A good example is the usage of TRIF by TLR-3 and TLR-4 
only, which leads to the activation of IFN-regulatory factor 3 (IRF3) and the 
induction of IFN-β (Hoebe et al., 2003; Yamamoto et al., 2003a).  
Whereas much progress has been made in the understanding of the TLR 
and adaptor families, other molecules in the Ig family have been mostly 
neglected. These orphan receptors include T1/ST2 (IL-1R4) (Brint et al., 2002; 
Klemenz et al., 1989; Mitcham et al., 1996), IL-1R-related proteins 1 (IL-1R5) 
(Parnet et al., 1996) and 2 (IL-1R6) (Lovenberg et al., 1996), IL-1R accessory 
protein ligand (IL-1R7)(Born et al., 1998), single immunoglobulin domain IL-1R-
related protein (SIGIRR, IL-1R8) (Mulero et al., 1999), IL-1R accessory protein-
like (IL-1R9)(Carrie et al., 1999), and IL-1R10 (Sana et al., 2000), which all 
contain  extracellular immunoglobulin domains and an intracellular TIR domain. 
Interestingly, like most of the IL-1 ligands, the majority of these IL-1Rs (IL-1R1, 
IL-1R2, IL-1R4, IL-1R5, IL-1R6, and IL-1R7) localize on chromosome 2 (Dale and 
Nicklin, 1999; Lafage et al., 1989; Patterson et al., 1993; Sims et al., 1995). 
However, the functional significance of this clustering is unclear. Recent 
discovery of IL-1Rrp2 as a receptor for IL-1F9, suggests that those orphan 
receptors may bind to other IL-1-like ligands (Debets et al., 2001). Among these 
orphan receptors, SIGIRR  is a negative regulator of Toll-like receptor-interleukin 
1 receptor signaling, which is the first member of IL-1R/TLR superfamily to exert 
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a negative modulating function on the signaling of other members of the 
superfamily (Wald et al., 2003). 
 
IL1RAcP forms complex with IL-1R and recruits MyD88 via its TIR domain 
The best characterized Ig family members include IL-1R and its accessory 
protein (IL1RAcP). The IL-1RI complex consists of two type I integral membrane 
proteins: IL-1RI and IL1RAcP (Greenfeder et al., 1995; Sims et al., 1988). Co-
expression of IL1RAcP is essential for complete IL-1 responsiveness (Hofmeister 
et al., 1997; Huang et al., 1997; Korherr et al., 1997; Wesche et al., 1997b).  As 
the second molecule of the IL-1RI complex containing three Ig domains, IL1RAcP 
does not bind IL-1β by itself (Greenfeder et al., 1995; Wesche et al., 1997b). 
Instead, IL1RAcP significantly increases, up to five fold, the affinity of IL-1RI for 
IL-1β. Similar to IL-1RI, IL1RAcP is widely expressed and always shows 
colocalization with IL-1RI except in rat brain (Radons et al., 2002). The Ig 
domains of IL-1AcP are involved in the assembly of IL-1RI and IL1RAcP into a 
heterodimer. It is still unknown whether IL-1RI and IL1RAcP form complexes in 
resting cells before ligand binding. IL-1β may change the conformation of IL-1RI 
which in turn recruits IL1RAcP. Alternatively, the binding of IL-1β may increase 
the affinity of IL-1RI-IL1RAcP interaction. Their heterodimerization depends on 
the Ig domains as well as the synergy of IL1RAcP box 3 and IL-1R1 boxes 1/2 
from TIR domain (Burns et al., 2000). 
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Specific sites in the cytoplasmic tail (TIR domain) are required for IL-1 
signaling, supported by reconstitution assays in IL1RAcP-lacking cells (Radons et 
al., 2002). Upon activation of the IL-1R complex, IL1RAcP recruits MyD88 via 
adaptor protein Tollip (Burns et al., 2000).  Mapping studies of the TIR domain of 
IL1RAcP indicated that its EE loop as well as highly conserved box 3 are required 
for MyD88 adaptor binding. The box 3 of the TIR domain of IL1RAcP (amino 
acids 538 to 542) is also essential for NFκB activation and IL-2 production 
(Radons et al., 2002). Adaptor protein Tollip may bind to amino acids 527 to 534 
of IL1RAcP. This signaling results in stabilization of IL-2 mRNA through c-Jun 
NH2-terminal kinase (JNK) and induction of optimal IL-2 promoter activity(Burns 
et al., 2000).  
 
MyD88 is the central relay station for IL-1R/TLR signaling pathway 
 
 
 
MyD88 is the common adaptor protein in multiple IL-1R/TLRs signaling pathways 
 
  MyD88 was originally described as a protein activated by IL-6 and 
expressed during myeloid differentiation (Lord et al., 1990). Human MyD88 was 
localized to chromosome 3 (Hardiman et al., 1997).  Recent studies indicated 
that MyD88, as an essential adaptor protein, integrates signals flowing from IL-
1R/IL1RAcP complex as well as from an array of other TLRs such as IL-18R, TLR-
2, TLR-4, and TLR9 (Akira, 2003). As shown in figure 4, upon activation of IL-1R 
complex by IL-1, a complex containing MyD88 and IRAK is formed, ultimately 
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leading to activation of NFκB (Cao et al., 1996; Wesche et al., 1997a). This initial 
IL-1RI/IL1RAcP – MyD88 adaptor interaction evoked by IL-1β is a critical step in 
its signaling to the nucleus and, therefore, represents an essential step in innate 
immunity, as well as a potential target for new anti-inflammatory agents (Bartfai 
et al., 2003; Li et al., 2005).  
 
TIR-TIR interaction of MyD88 is an essential step in IL-1R/TLR signaling  
MyD88 has a bi-domainal structure comprised of an amino terminal death 
domain(DD), similar to the intracellular segments of TNF receptor 1 (TNFR1) and 
FAS, and a carboxyl terminal TIR domain with a short intermediate segment in 
between (figure 6) (McGettrick and O'Neill, 2004; Wesche et al., 1997a). The 3-
dimensional structure of the TIR domain has an overall fold with a central five-
stranded parallel β-sheets surrounded by five α helices, which are  similar to the 
bacterial chemotaxis protein CheY (Rock et al., 1998). A splice variant of MyD88 
(MyD88s) lacking the intermediate segment fails to recruit IRAK4 which is 
required for phosphorylation of  IRAK1, thus it functions as a negative regulator 
of IL-1R/TLR/MyD88-triggered signals (Burns et al., 2003). Until recently, our 
understanding of structural characteristics of IL-1R complex-MyD88 adaptor 
interaction was limited.  
MyD88 protein interacts with other TIR-domain containing proteins via the 
TIR domain mediated heterotypic dimerization (Burns et al., 1998). MyD88 
protein can also form homotypic dimers via both the TIR and death domains 
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Figure 6. MyD88 contains TIR domain and death domain.  
A, MyD88 is comprised of an amino terminal death domain (DD) similar to the 
intracellular segments of TNF receptor 1 (TNFR1) and FAS, as well as a carboxyl 
terminal TIR domain with a short intermediate segment in between. There is a 
short intermediate domain (ID). A splice variant without the ID domain, MyD88s, 
failed to recruit IRAK4 which is required for phosphorylation of IRAK1. MyD88s 
may function as a negative regulator of IL-1R/TLR/MyD88-triggered signals. 
B, topology diagram of the TIR Domain. Parallel beta-sheets (with β-strands A-E 
as yellow triangles) are seen at their C-terminal ends; α-helices (red circles 
labeled A-E) link the β-strands; chain connections are to the front (visible) or 
back (hidden). Two connecting chains BB loop (between α-B helix and β-B strand) 
and EE loop (between α-E helix and β-E strand) will be off particular interest to 
this study of MyD88. Highly conserved sequences denoted Box 1, 2 and 3 are not 
depicted in this topology diagram (see Figure 8 and 9).   
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(Burns et al., 1998). As the key relay station in multiple IL-1R/TLR signaling 
pathways, the structure-function relationship of MyD88 is of special significance. 
Dominant-negative constructs of MyD88, lacking the death domain, block NFκB 
activation by multiple ligands in HEK293 cells when co-transfected together with 
the multiple receptors such as IL-1R, TLR-2, TLR-4, or TLR-9  (Bauer et al., 2001; 
Muzio et al., 2000).  Upon activation of IL-1R complex by IL-1, MyD88 forms a 
complex containing MyD88, IRAKs and Tollip which leads ultimately to activation 
of NFκB (Cao et al., 1996; Wesche et al., 1997a). The association of MyD88 with 
the activated IL-1R complex is evidenced by  coimmunoprecipitation experiments 
(Wesche et al., 1997a).  
The significance of MyD88 in multiple IL-1R/TLR signaling is further 
demonstrated by recent studies in MyD88 deficient mice, which do not respond 
to ligands such as IL-1, IL-18, peptidoglycan, and CpG-DNA (Adachi et al., 1998; 
Kawai et al., 1999). However, in response to LPS and polyI:C,  NFκB and MAPK 
activation still occurred albeit with  slower kinetics despite the fact that cytokine 
production in macrophages and dendritic cells of these mice was impaired 
(Kaisho et al., 2001; Kawai et al., 2001; Yamamoto et al., 2003a). The existence 
of a MyD88-independent pathway in signaling initiated by TLR-4 and TLR-3 can 
be explained by the presence of other adaptor molecules involved in TIR domain-
mediated signaling. A total of five such adaptor proteins are known to exist in 
mammals so far. These proteins are not entirely promiscuous in their interaction 
with TLRs, but rather, show preferential association with individual family 
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members, giving a particular character to the signals that distinct micro-
organisms initiate.  
 
Other adaptor proteins are involved in IL-1R/TLRs signaling   
The second TIR domain containing adaptor protein is identified as MyD88-
adaptor like (MAL/TIRAP) (Fitzgerald et al., 2001; Horng et al., 2001). Compared 
with MyD88, MAL also contains a COOH-terminal TIR domain, but there is no 
death domain on the NH2-terminus (figure 4). The TIR domain of MAL interacts 
with the TIR domain of MyD88 and TLR-4, but not the IL-1R complex. Dominant-
negative constructs of MAL/TIRAP specifically block LPS-induced TLR-4, but not 
IL-1R or TLR-9 signaling. Although MAL knockout mice are impaired in their 
responses to TLR-4 and TLR-2 ligands, LPS-induced dendritic cell maturation and 
activation of interferon-inducible genes is normal (Horng et al., 2002; Yamamoto 
et al., 2004). This finding suggests that MAL plays a role in the MyD88-
dependent pathway shared by TLR-2 and TLR-4, instead of a distinct pathway 
from MyD88.  
The third adaptor molecule identified recently is TIR domain-containing 
adaptor inducing IFN-beta (TRIF) (Yamamoto et al., 2002). TRIF, but neither 
MyD88 nor MAL/TIRAP, preferentially activates the IFN-ß promoter. Dominant-
negative TRIF blocks polyI:C – induced, TLR-3-dependent activation of both the 
NFκB-dependent and IFN-β-dependent promoters, indicating that TRIF is the 
adaptor in the MyD88-independent TLR-3 signaling pathway (figure 4). Additional 
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support for the involvement of TRIF in this pathway was provided by its co-
immunoprecipitation with TLR-3. TRIF may also be involved in LPS-induced 
MyD88-independent signaling in TLR-4 pathway (Hirotani et al., 2005). However, 
TRIF does not bind TLR-4 directly, suggesting the existence of another adaptor 
to bridge TRIF and TLR-4. 
The fourth adaptor is named TRIF-related adaptor molecule (TRAM), or TIR 
domain-containing protein (TIRP) (Bin et al., 2003; Fitzgerald et al., 2003; 
Oshiumi et al., 2003). The interactions between TRAM and the TLRs were 
examined by yeast two-hybrid analysis, and the results indicate that TRAM binds 
to TLR-4 as well as to TLR-3 albeit weakly. TRAM has not been found to bind to 
the TIR domains of TLR-2, TLR-5, TLR-6, TLR-7, TLR-8 and TLR-9 (Oshiumi et al., 
2003). TRAM can form homodimers as well as heterodimers with TRIF but can 
not interact with MyD88 or MAL, indicating that TRAM may play a role in MyD88-
independent TLR-4 signaling (figure 4). The involvement of TRAM in TLR-4-
initiated signaling is supported by the evidence from a mouse gene knock out 
study (Yamamoto et al., 2003b). TRAM-deficient mice showed impaired LPS-
induced cytokine production but retained a normal response to the ligands for 
TLR-2, TLR-3, TLR-7, TLR-9 as well as to stimulation with IL-1β. The activation 
of the MyD88-dependent pathway by LPS was unaffected in the TRAM-deficient 
mice but the activation of the MyD88-independent pathway was abolished.  
Recently, the fifth TIR domain-containing adaptor was discovered. This 
adaptor is named SARM (SAM and ARM-containing protein). SARM is composed 
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of an N-terminal series of β-catenin/armadillo motifs and two tandem SAM 
domains adjacent to a C-terminal TIR domain (Mink et al., 2001). The SAM 
domain is known to be involved in signaling by homotypic- and heterotypic-
oligomerization. The ARM motif is a 40-amino acid tandem repeat that mediates 
the interaction between β-catenin and its ligand, and can form interactions with 
other proteins, for example, the small GTPase Ras. Only three Caenorhabditis 
elegans proteins are thought to have TIR domains and two out of three are 
closely related to SARM. Strikingly, unlike the other adaptor proteins, SARM is 
the only TIR-containing adaptor that did not induce NFκB-dependent reporter 
activity (Kaiser and Offermann, 2005). Orthologs of SARM are found in nematode, 
insect, and fish (Kaiser and Offermann, 2005). Though the function of SARM 
remains unclear, the nematode ortholog of SARM, TIR-1, is necessary for the 
cellular response to fungal infection and signals independently of the single TLR 
expressed in Caenorhabditis elegans  (Couillault et al., 2004). Overexpression of 
the TIR domain of SARM partially inhibits IL-1 induced activation of NFκB 
reporter gene in HepG2 cells (Sethman and Hawiger, unpublished data). Thus, 
SARM may have a role in IL-1R/TLR-related innate immune responses. The fact 
that SARM contains both catenin/armadillo motifs and a TIR domain suggests 
that it may be imported into the nucleus. Further experiments including studies 
of SARM- deficient mice are needed to unveil the involvement of SARM in TLR 
signaling. The diagram depicting the domainal structure of these five adaptor 
proteins discussed above is shown in figure 7. While all adaptor proteins contain 
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Figure 7. Schematic diagram of five members in the adaptor family 
of IL1R/TLR superfamily. MyD88 is the only adaptor which contains a 
death domain (DD). TRIF and SARM are considerably longer than the other 
TIR domain containing adaptor proteins. Unlike the other four adapter 
proteins that contain the TIR at the C terminus, TRIF has 400 amino acid at 
the N-terminus and a C-terminal extension. SARM is composed of an N-
terminal series of   β-catenin/armadillo motifs and two tandem SAM domain 
before a C-terminal TIR domain. MAL/TIRAP and TRAM are the smaller in 
size among the five adaptors, which contain short N-terminal extensions 
with no known homology to other proteins.  
Modified from Kaiser W.J. et al, The Journal of Immunology, 2005, 174: 
4942-4952.  
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the TIR domain, only MyD88 bears the death domain (DD) and is uniquely 
involved in IL-1 beta signaling. 
The IL-1β signaling pathway depends on an orchestrated interplay of 
intracellular protein-protein interactions(Akira and Sato, 2003; Dinarello, 2002; 
Yamamoto et al., 2004). MyD88 plays a pivotal role in these interactions by 
directing the flow of signals from IL-1β-occupied cognate receptor complexes to 
downstream signal transducers (Akira and Sato, 2003; Yamamoto et al., 2004). 
Within MyD88, its TIR domain provides an interacting surface for heterotypic 
interaction with the TIR domain of IL1RAcP (Akira and Sato, 2003). Therefore, 
we embarked on structure-function analysis of the MyD88 TIR domain that is 
essential for the transduction of IL-1β signaling to downstream effector(s).  
 
 
Formulation of working hypothesis and experimental strategy 
MyD88 integrates signals flowing from IL-1R/IL1RAcP(Akira, 2003). This 
initial IL-1 receptor – MyD88 adaptor interaction evoked by IL-1β is a critical step 
in its signaling to the nucleus. Therefore, this interaction represents a potential 
target for new anti-inflammatory therapeutic agents. MyD88 has a bi-domainal 
structure comprised of amino terminal death domain and carboxyl terminal TIR 
domain (McGettrick and O'Neill, 2004). Interaction between IL1RAcP and MyD88 
characterized in coimmunoprecipitation studies has indicated that the EE loop 
and box 3 of the TIR domain in IL1RAcP were required for MyD88 binding 
(Radons et al., 2002). However, no information was available regarding the 
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corresponding interactive sites on MyD88. We hypothesize that MyD88 interacts 
with IL1RAcP via specific surface area(s) in its TIR domain, most likely located 
within the three conserved boxes.  
To study the molecular determinants of MyD88 TIR domain interactions in 
the IL-1β signaling pathway, a series of truncation/deletion mutants of the 
MyD88 TIR domain were made. Using an established NFκB reporter assay in 
HEK293T cells transiently transfected with these mutants, I demonstrated that 
the TIR domain mediates a dominant negative effect on IL-1β- induced NFκB 
activation. The integrity of the TIR domain is important for its function in binding 
to the IL-1R complex. MyD88 TIR mutants containing alanine substitutions of 
putative interactive sites were generated and the significance of these selected 
residues was evaluated in NFκB activation, cytokine production, and direct 
interaction with IL1RAcP. Computational modeling and docking study were 
applied for further verification of the identified interactive sites. It is anticipated 
that these structural-functional studies of MyD88 will help to establish the 
molecular determinants of MyD88 TIR domain interactions in the IL-1β signaling 
pathway.  
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CHAPTER II 
 
ANALYSIS OF MYD88 TIR DOMAIN IN IL-1Β PATHWAY 
 
Synopsis 
Myeloid differentiation primary response gene (MyD88) is the essential 
adaptor protein that integrates and transduces intracellular signals generated by 
multiple Toll-like receptors (TLRs) including the receptor complex for interleukin 
(IL)-1β, a key inflammatory cytokine. The IL-1β receptor complex interacts with 
MyD88 via the Toll/IL-1 receptor (TIR) domain. Here we report structure-
function studies that further define the MyD88 TIR domain binding sites involved 
in IL-1β-induced protein-protein interactions. The MyD88 TIR domain, employed 
as dominant negative inhibitor of IL-1β signaling to screen MyD88 TIR mutants, 
loses its suppressing activity upon truncation of Box 3. Accordingly, mutations of 
Box 3 residues 285-286 reversed the dominant negative effect of the MyD88 TIR 
domain on IL-1β-induced and NFκB-dependent reporter gene activity and IL-6 
production. Moreover, mutations of residues 171 in helix αA, 195-197 in Box 2, 
and 275 in βE strand had similar functional effects. Strikingly, only mutations of 
residues 195-197 eliminated the TIR-TIR interaction of MyD88 and IL1RAcP while 
substitution of neighboring canonical proline 200 by histidine was without effect. 
Mutations in Box 2 and 3 prevented homotypic MyD88 oligomerization via the 
33
TIR domain. Based on this structure-function analysis, a 3-dimensional docking 
model of TIR-TIR interaction between MyD88 and IL1RAcP was developed. 
 
Introduction 
The importance of the Toll-like receptor (TLR) family in innate immune 
responses to microbial pathogenic molecular patterns is well established. Two 
members of this family recognize key inflammatory cytokines IL-1 and IL-18.  
IL-1 is one of the most potent inflammatory cytokines and is responsible 
for fever, leukocytosis, thrombocytosis, and production of IL-6 and other 
cytokines (Akira and Sato, 2003; Dinarello, 2002; Yamamoto et al., 2004). The 
signals generated by the association of IL-1 and its cognate receptor complex, 
formed by two type 1 transmembrane proteins -- IL-1 receptor I (IL-1RI) and IL-
1 receptor accessory protein (IL1RAcP) -- are transduced by their cytoplasmic 
segments denoted as the Toll/IL-1 receptor (TIR) domain. The TIR domain is 
shared with Drosophila Toll, mammalian TLRs, and cytoplasmic adaptors 
exemplified by MyD88 (McGettrick and O'Neill, 2004). 
Although the biochemical processes of NFκB activation by IL-1 have been 
well characterized, the elucidation of the IL-1 receptor proximal signaling 
mechanisms mediated by TIR-TIR domain interaction has just begun within the 
last few years. Biochemical and genetic studies suggest that the initial IL-1 
receptor-MyD88 adaptor interaction evoked by IL-1 binding to its receptor 
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complex is a critical step in its signaling to the nucleus (Adachi et al., 1998; 
Kawai et al., 1999).  
The bi-domainal structure of MyD88 has been well characterized 
(McGettrick and O'Neill, 2004). MyD88 adaptor protein is composed of an amino-
terminal death domain and a carboxyl-terminal TIR domain with a short 
intermediate linker segment. The TIR domain of MyD88 is thought to bind with 
that of the IL-1R, and the death domain interacts with the death domain found at 
the NH2 terminus of IRAKs. Upon ligand IL-1 binding, IL-1RI/IL1RAcP complex 
recruits MyD88 via its TIR domain (Wesche et al., 1997a). In addition, IL-1RI-
associated kinases are recruited to an IL-1RI/IL1RAcP complex by death domain 
including IRAK (Huang et al., 1997; Wesche et al., 1997b), IRAK-2 (Volpe et al., 
1997), IRAK-4 (Li et al., 2002)  and IRAK-M (Kobayashi et al., 2002).  
Although biochemical evidence indicates that activation of IL-1R involves 
the recruitment of specific post-receptor signaling complexes including IL-1R1, 
IL1RAcP, MyD88 and IRAKs, there is only limited structural information regarding 
protein-protein interaction within these complexes. In fact, the only structures 
solved to date are those of the isolated TIRs from TLR-1 and 2 (Xu et al., 2000). 
The 3-dimensional structures of these molecules have an overall fold with a 
central five-stranded parallel β-sheets surrounded by five helices, which are  
similar to the bacterial chemotaxis protein CheY, confirming the prediction made 
by Rock et al., (Rock et al., 1998). Most of the conserved residues in TIR 
domains are buried in the center of the molecule, but some are solvent-exposed. 
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This exposure may form an interaction surface to which other TIR domain 
containing proteins, such as MyD88 or other adaptor proteins, can bind in 
response to signaling. Here we report the molecular determinants of MyD88 TIR 
domain interactions in the IL-1-signaling pathway. 
In terms of its structural features, the MyD88 TIR domain contains three 
highly conserved motifs denoted Box 1, 2, and 3 (figure 8 and 9). Box 2 forms a 
loop denoted the BB loop that contains an invariant proline residue at position 
200. A single amino acid mutation in the corresponding proline residue to 
histidine in the TLR-4 receptor renders C3H/HeJ mice hyporesponsive to LPS. 
The BB-loop connects the second β-strand (β-B) and second α-helix (α-B); a 
corresponding change also abolishes the ability of TLR-2 to interact with MyD88 
in vitro (Poltorak et al., 1998). This proline residue is thought to be important in 
multiple TIR domain- mediated signaling pathway from receptors and adaptors 
based on mutation of invariant proline to histidine (for example, TLR-2, TLR-4, 
IL1RAcP, and MAL/TIRAP) (Akira, 2003; McGettrick and O'Neill, 2004). These 
canonical examples indicate that conserved structural motifs in the TIR domain 
of TLRs and their adaptors play a significant role in proinflammatory ligand-
initiated intracellular interactions between these proteins. 
Depending on the recognition of distinct ligands by TLRs, the preferential 
usage of its adaptors may require different interacting sites in the TIR domain of 
the same adaptor or an alternative adaptor. The latter applies to TLR-3, which 
requires its adaptor, TRIF, rather than MyD88 for signaling by viral double-
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Figure 8. Sequence alignment of the TIR domain of human MyD88 and 
TLR-2. The crystal structure of the TIR domain of TLR-2 was used for homology 
modeling of MyD88-TIR performed with T_COFFEE. Box1-3 are underlined. 
Residues within MyD88 TIR domain substituted with alanine are shown in bold. 
Proline at position 200 is also shown in bold and substituted with histidine in this 
study.  
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Figure 9. Structural model of the MyD88 TIR domain with 
conserved box 1-3.  Comparative modeling of MyD88-TIR was 
performed with SWISS-MODEL by aligning to crystal structure of hTLR2 
optimized by GROMOS 96 and visualized by DeepView/Swiss-pdb viewer.   
A, structural features representing the conserved boxes of the MyD88 TIR 
domain are shown in yellow (Box 1), purple (Box 2) and blue (Box 3).   
B, electrostatic potential of MyD88 TIR with the indicated position of 
structural features (boxes 1-3) corresponding to same in panel A. The 
color scale is as follows: red (most negative) and blue (most positive). 
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stranded RNA. Conversely, TRIF mediates signaling induced by interaction of LPS 
with TLR-4 in the absence of MyD88 (Akira, 2003). Different usage of the five 
currently known adaptor proteins may contribute to the specificity and selectivity 
of signaling events stimulated by different ligands for IL-1R/TLR family members.  
We hypothesized that signaling evoked by IL-1 through its cognate 
receptor complex may depend on different interactive sites on the TIR domain of 
MyD88 other than the recently reported sites involved in MyD88 interaction with 
the TIR domains of TLR-2 and TLR-4 (Dunne et al., 2003).  
 
Results 
Our stepwise experimental strategy consisted of analysis of the secondary 
and tertiary structure of the MyD88 TIR domain. These data were extrapolated 
from the available crystal structure of TLR-2 TIR domain (Xu et al., 2000), which 
contains highly conserved Box 1-3 (figure 8), and we used as a comparative 
template for developing a structural model of the MyD88 TIR domain (figure 9). 
Drawing from these modeling studies, two series of mutagenesis experiments 
were performed. In the first set of experiments, a construct containing only the 
TIR domain of MyD88, as its dominant negative inhibitor, was mutated and the 
expressed mutants were screened for their inhibitory effect on IL-1β-induced 
signaling to the nucleus. In the second set of experiments, selected TIR residues 
were mutated in a full-length MyD88 to assess the impact of specific 
replacements on the heterotypic interaction of MyD88 with IL1RAcP and on 
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homotypic MyD88 oligomerization mediated by its TIR domain. The results from 
these structure-function analysis led us to the development of the 3-dimensional 
docking model of MyD88 interaction with IL1RAcP mediated by their respective 
TIR domains (Li et al., 2005).     
 
 
Activation of NFκB by overexpression of MyD88 and its death domain is abolished 
in Phe56Asn 
 
Many adaptor proteins involved in signal transduction form homo- and 
heterotypic interactions through similar domains. MyD88 is composed of N-
terminal death domain (DD) and C-terminal TIR domain, each of which promotes 
similar-domain interactions. As the death domain is a region that frequently 
promotes such interactions, MyD88 and its deletion mutations were therefore 
analyzed for NFκB activation using reporter gene activity assay (figure10A). To 
assess whether the death domain mediates NFκB activation, various point and 
deletion mutants of MyD88 were generated. Phe56 was chosen for mutagenesis 
based on sequence alignment of the MyD88 DD with the DD of Fas (Hofmann 
and Tschopp, 1995). A similar mutation at this position corresponds to the lprcp 
mutation  known to abolish cytotoxic signaling of Fas by disrupting the 
conformation of the death domain (DD) as revealed by NMR spectroscopy 
(Huang et al., 1996). As shown in figure 10B, overexpression of MyD88 induces 
NFκB activation, consistent with a previous report (Burns et al., 1998). 
Overexpression of death domain can also activate NFκB as well as AP-1, probably 
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Figure 10. NFκB-dependent reporter gene activation by 
overexpression of MyD88 and its mutants.  
A, schematic diagram of NFκB reporter gene activity assay driven by IL-1β or 
MyD88 overexpression.  
B, the dependence of reporter gene activity on NFκB activation. HEK 293T 
cells (2 × 105) were transfected with 1 µg of IκBαΔN or control vector 
together with 1 µg  κB-luc and 1 µg of RL-TK, 1 µg of MyD88 (dark bar); or 
1.5 µg of empty vector (open bar). Note that cells transfected with IκBαΔN 
display minimal reporter gene activation.   
C, Full-length MyD88 and MyD88 mutants are schematically represented. The 
stripped  and gray rectangles represent the death and TIR domains, 
respectively. MyD88 containing a point mutation, F56N, in the death domain 
is represented by a black circle, and P200H, in the TIR domain is represented 
by a open circle.  
D, concentration and structure dependenct NFκB activation MyD88 mutants. 
HEK 293T cells were transfected with 1 µg of κB- luc, 1 µg of RL-TK, and the 
indicated MyD88 constructs (0.4 and 2 µg of each).  
E, Co-expression of TIR domain can inhibit reporter gene activation induced 
by forced expression of MyD88.  Note that the reporter gene activation by 
ectopically expressed MyD88 is inhibited by co-expression of TIR domain, but 
not DD-F56N and TIR-P200H mutants. κB-luc activities in C-D were 
determined 24 h after transfection and normalized on the basis of RL-TK 
level. Values shown are averages for representative experiments in which 
each transfection was carried out in triplicate. 
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due to homotypic dimerization. However, overexpression of mutants carrying 
Phe56 to Asn in full length MyD88 (MyD88 F56N) and in its death domain (DD-
F56N) abolished this activation of NFκB (figure 10D). To further assess the 
function of Phe56, I conducted co-expression experiments with DD-F56N and 
MyD88 in HEK 293T cells. DD-F56N can not inhibit the NFκB activation induced 
by overexpression of MyD88, indicating that DD-F56N can not associate with 
MyD88 (figure 10E). There are at least two possible explanations for this loss-of-
function mutation: first, Phe56 may be involved in the interaction and recruitment 
of downstream signaling molecules like IRAK; second, the Phe56 may be involved 
in the homotypic dimerization. Burns et al previously reported that the Phe56 Asn 
mutation abolished the interaction of death domains using a yeast two-hybrid 
assay, suggesting the latter scenario: the Phe56Asn abolished the NFκB activation 
via disruption of the dimerization mediated through the death domain of MyD88 
(Burns et al., 1998). 
Although forced expression of full length MyD88 and MyD88-DD strongly 
induced NFκB activation in 293T cells, as previously reported by others (Burns et 
al., 1998), the truncation mutants TIR and TIR-P200H were inactive. MyD88 
induced the activity of NFκB reporter gene in a dose-dependent manner and this 
activation was abolished by co-expressed IκBαΔN, an IκBα degradation-resistant 
mutant form that blocks nuclear translocation of NFκB (Boothby et al., 1997; Liu 
et al., 2004b). Thus, these results confirmed the dependence of reporter gene 
activation on NFκB (figure 10B).   
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NFκB activation following transient transfection of MyD88 constructs was 
also observed with the MyD88-P200H mutant expression vector, suggesting that 
this canonical proline200 is not involved in MyD88-dependent signaling. However, 
this result can also be explained by the finding that intact death domain alone is 
capable of inducing NFκB activation. As described in the previous chapter, the 
proline 200 residue is highly conserved amongst the members of IL-1R/TLR 
family. The experimental evidence concerning its potential role in IL-1β signaling 
will be shown later in this chapter.  
 
Structural characterization of MyD88 TIR domain 
To study the TIR-TIR interaction of MyD88, a computational model of its 
TIR domain was established. This TIR domain is modeled on the basis of the 
crystal structure solved for TLR-2 (Xu et al., 2000). As shown in figure 6B, it has 
an α-β fold similar to that of the bacterial chemotaxis protein CheY and  
contains three highly conserved motifs termed Boxes 1, 2, and 3 (Akira and Sato, 
2003). On the basis of primary structure alignment obtained with the program T-
COFFEE, presented in figure 8, the crystal structure of human TLR-2 TIR domain 
(Protein Data Bank pdb files of 1O77) was selected as the best template for the 
MyD88 TIR domain with 31% identity and >50% similarity. Results obtained 
from the server were visualized with the DeepView program (Swiss Pdb viewer). 
As shown in figure 9, the secondary structure of the TIR domain consists of five 
β strands: β-A, β-B, β-C, β-D and β-E forming the core of molecule which is 
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surrounded by five α-helices: α-A, α-B, α-C, α-D and α-E. The five loops AA, BB, 
CC, DD and FF form specific links between β-strand and corresponding α-helix. 
In terms of its tertiary structure, as depicted in figure 9, the MyD88 TIR domain 
has a globular shape. Among three highly conserved motifs, Box 1, located at the 
N-terminus of the TIR domain, partially forms a β-A strand. Box 2 makes the 
second part of the BB loop, while Box 3 creates the first part of α-E helix, which 
is located at the C-terminus of MyD88 TIR domain. Analysis of the distribution of 
charged residues indicates that the molecular surface of MyD88 TIR domain is 
mostly positively charged (blue) with a few distinct negatively charged knobs 
(red). They surround a larger swatch of negatively charged surface (red), formed 
by three loops, AA, BB, and partially DD, and α-C helix. Moreover, the BB loop, 
projects from the globular TIR domain, forming a quasi-plane on its surface. 
 
Box 3 of MyD88 TIR domain is involved in IL-1β-induced signaling  
To study the molecular determinants of MyD88 TIR domain interactions in 
the IL-1β signaling pathway with its mutants, human embryonic kidney 293T 
cells were transiently transfected with κB reporter gene. The HEK 293T cells 
respond to IL-1β in a wide range of concentrations (0.03 – 30 ng/mL) in a dose 
dependent manner (figure 11A). Co-expression of IκBαΔN (kindly provided by 
Dean W. Ballard, Vanderbilt University), a degradation-resistant mutant form of 
IκBα with truncation at its N-terminus, resulted in complete inhibition of NFκB 
reporter gene activity (figure 10B). However, HEK 293T cells did not respond to 
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Figure 11.  Inhibition of IL1β-induced κB reporter gene activity by 
MyD88 TIR domain.  
A, IL1β-induced κB reporter gene activation was inhibited in HEK 293T cells 
transfected with MyD88 TIR (152-296). The HEK 293T cells were transfected 
with MyD88 TIR together with κB-luc (5µg) and RL-TK (2.5µg). After 24 h, IL1β 
was added at indicated concentrations for 6 h. NFκB-reporter gene activity was 
determined and normalized on the basis of RL-TK activity.  
B, diagram of deletion mutants containing MyD88 TIR domain and the expression 
level in transfected 293T cells. All these mutants are inserted into pcDNA3.1 
using PCR at BamH I and EcoR I sites. TIR and TIR∆C(152-283) were selected 
for further study.  
C, truncation of the COOH terminal segment of TIR (TIR∆C) reverses the 
inhibitory effect of the TIR domain. HEK 293T cells were transfected with 
MyD88-TIR or MyD88-TIR∆C (152-283) constructs together with κB-luc (5 µg) 
and RL-TK (2.5 µg). After 24 h, IL1β was added at a concentration of 10 ng/mL 
for 6 h. NFκB reporter gene activity was measured and normalized on the basis 
of RL-TK activity. Insets, Expression levels of MyD88-TIR and MyD88-TIR∆C 
(152-283) in transfected HEK 293T cells determined by immunoblotting with anti-
AU1 antibody. A representative experiment is shown from the series of three 
performed in triplicate. Error bars indicate the ± S.E. of the mean value of 
triplicate. 
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IL-1β in NFκB-dependent reporter gene activity assay after ten passages. Thus, 
293T cells freshly thawed were used throughout this study. In previous reports 
of IL-1β- induced NFκB signaling, the most commonly used cell line is human 
embryonic kidney cells 293-IL-1RI, which was stably transfected with human IL-
1RI (Cao et al., 1996; Radons et al., 2003). 
Kappa B reporter gene activity assay was used to test the MyD88 TIR 
domain as a dominant negative inhibitor of IL-1β-induced signaling to the 
nucleus. As documented in figure 11A, HEK 293T cells transfected with plasmid 
containing NFκB-dependent luciferase gene responded to sub-nanogram doses of 
IL-1β. This activation reached its maximum at 1 ng/mL of IL-1β attesting to the 
high sensitivity of transfected 293T cells to this inflammatory cytokine. 
Consistent with prior studies (Burns et al., 1998; Dupraz et al., 2000), the MyD88 
TIR domain, used as a dominant negative inhibitor of IL-1β signaling, almost 
completely suppressed its activating effect on the reporter gene over a wide 
range of IL-1β concentrations (figure 11A). The TIR domain of MyD88 contains 
segments of conserved sequences, namely, Box 1, 2, and 3 shared by IL-1R/TLR 
superfamily members (see previous chapter). Whether all of these boxes are 
necessary for the function of this dominant negative inhibitor of IL-1β signaling is 
an important question to address. To study the molecular determinants of the 
MyD88 TIR domain interactions in IL-1β signaling pathway, I engineered deletion 
mutants of MyD88 TIR domain to screen them in an established reporter gene 
activity assay for their inhibitory effect on IL-1β-induced signaling. As depicted in 
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figure 11B, the TIR domain mutants include deletions of N-terminus Box 1 
(TIRΔN, 188-296), Box1 and Box 2 (TIR-C, 203-296), Box 1 and Box3 (TIR-Box2, 
188-203), C-terminus Box 3 (TIRΔC, 152-283), as well as a deletion of the 
segments after Box 2 (TIR-N, 152-203).  These cDNA fragments were generated 
by PCR to add an N-terminal AU1-tag and then cloned into pcDNA3.1 at BamH I 
and EcoR I sites under control of CMV promoter.  
 Sequence-verified mutants were transiently transfected into HEK 293T 
cells to test them for expression and potential inhibitory effect on IL-1β-induced 
NFκB signaling. As shown in figure 11B,  only TIRΔC missing a segment 
encompassing Box 3 (282KSWFWTRLAK291) located at the COOH-terminus of 
MyD88 TIR domain was expressed at the level comparable to that of intact 
MyD88 TIR upon transient transfection (see inset). This deletion in TIRΔC caused 
the loss of the dominant negative inhibitory function of MyD88 TIR (figure 11C) 
suggesting that Box 3 was essential for IL-1β-induced signaling. Other mutants 
were undetectable in transfected HEK 293T cells by either immunoblotting 
analysis or immunohistochemical staining with anti-AU1 antibody (data not 
shown). The fact that the Box 3 deletion mutant was expressed in transfected 
cells at a level comparable to the intact MyD88 TIR domain but deletion mutants 
lacking Box 1, Box 1&2, Box 1&3 were not expressed, suggests that Box 1 and 2 
are important for TIR domain structural integrity and stability in HEK 293T cells.  
Based on the results presented above, Box 3 of the MyD88 TIR domain is 
essential for IL-1β-induced NFκB signaling. Whether Box 3 is involved in MyD88 
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interaction with IL1RAcP or in homodimerization of MyD88 was determined in 
subsequent experiments (see below). Significantly, prior studies based on the 
yeast - two hybrid assays indicated that MyD88-TIR did not dimerize with  a 
deletion mutant missing 15 amino acids at the C terminus (Burns et al., 1998; 
Dupraz et al., 2000). 
 
Site-directed mutagenesis of MyD88 TIR domain leads to loss of its inhibitory 
activity toward IL-1β–induced signaling  
 
The involvement of Box 3, as compared to Boxes 1 and 2, in signaling 
induced by IL-1β and mediated by the MyD88 TIR domain, was further analyzed 
in a series of mutagenesis experiments. Mutations of the TIR domain (residues 
152-296) included two bulky hydrophobic residues (F285 and W286) in the 
highly conserved short motif in Box 3 (SWFWTRL) and proline at the position 200. 
The canonical Pro712His mutation in TLR-4 renders C3H/HeJ mice hyporesponsive 
to LPS (Poltorak et al., 1998). Furthermore, alignment of members of the TLR 
family revealed two short motifs in Box 1 (PERFDAF) and Box 2 (DRDVLPG) that 
are most conserved along with Box 3 motif in MyD88 TIR domain. Alanine 
substitutions were primarily based on selection of charged residues either in the 
conserved region or predicted to be on the surface (figure 8). In addition, two 
mutations, V204 and Q229 were in the region predicted to interact with MAL 
(Dunne et al., 2003). The expression level of all the TIR domain mutants and 
their functional analysis of NFκB reporter gene activation are depicted in figure 
12.  
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Figure 12. Selected MyD88 TIR domain mutants with “loss of 
inhibition” phenotype.  
A, functional analysis of MyD88 TIR domain mutants. MyD88 TIR domain 
mutants that did not inhibit NFκB reporter gene activity 2.5 fold or more 
were considered “loss of inhibition” phenotype as compared to the 
dominant negative inhibitory effect of wild type MyD88 TIR domain. Blue, 
mutants with “loss of inhibition” phenotype, include D171A (T1), 
D195A/R196A/D197A (T2), D275A (T4), F285A/W286A (T5). Pink, 
mutants that expressed and displayed similar phenotype as wild type TIR, 
including P200H (T3). Gray, mutants that were not expressed. T1 to T5 
were selected for further functional analysis. Box1-3 are underlined. 
Residues within MyD88 TIR domain substituted with alanine are shown in 
bold. Proline at position 200 is also shown in bold. 
B, location of T1, T2, T4 and T5 mutants which displayed “loss of 
inhibition” phenotype on the ribbon structure of MyD88 TIR domain. 
Conserved boxes of MyD88 TIR domain are shown in yellow (Box 1), 
purple (Box 2) and blue (Box 3).  P200H (T3) is located on Box 2 (side 
chain not shown). 
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The expression of mutants varied as compared to that of the wild type 
MyD88 TIR domain (Figure 12). These mutants can be divided into three groups: 
the first group, TIR mutants that were expressed at a level comparable to that of 
the wild type MyD88 TIR domain and displayed a loss of inhibition of IL-1β - 
induced reporter gene activity. They include D171A (T1), D195A/R196A/D197A 
(T2), D275A (T4), F285A/W286A (T5). The second group encompasses MyD88-
TIR mutants that are not expressed presumably due to misfolding and/or 
degradation. They include D162A, D225A/D226A, K256A and K258A. The third 
group includes TIR mutants which were expressed and inhibited IL-1β -induced 
reporter gene activation comparable to that of the wild type TIR. This group 
included the remainder of the mutants. Of particular significance is the result 
with the P200H mutant (T3), analogous to the Pro712His mutation in TLR-4, 
which is responsible for the LPS hyporesponsiveness of C3H/HeJ mice (Poltorak 
et al., 1998). Similar loss of signaling in other TIR-containing molecules like 
MAL/TIRAP (Horng et al., 2001) and IL1RAcP (Radons et al., 2003; Radons et al., 
2002) were reported, indicating that the invariant proline in the BB loop of Box 2 
in these molecules is one of the interactive sites for other TIR domains-
containing proteins. In striking contrast, a similar mutation (P200H, T3) in the 
MyD88 TIR domain, tested over a range of input concentrations, did not change 
the dominant negative effect of MyD88 TIR on IL-1β-induced reporter gene 
activation in HEK 293T cells (figure 13A). These cells showed a similar level of 
expression of the intact and mutant TIR proteins (insert in figure 13A). This 
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Figure 13. Functional analysis of MyD88 TIR domain mutants 
tested in κB reporter gene activity assays.  
A, Concentration-dependent inhibition of NFκB reporter gene activity by 
wild-type and T3 mutant (Proline200Histidine);  
B, Inhibition of κB reporter gene activity by mutants T1, T2, T4, and T5. 
HEK 293T cells were transfected with MyD88-TIR or its mutant constructs 
(1-15 µg in panel A and 12.5 µg in panel B) together with κB-luc and RL-
TK. After 24 h, IL-1β was added at a concentration of 10 ng/mL for 6 h. 
Cells were harvested and split for both reporter assay and immunoblotting. 
κB reporter gene activity was analyzed and normalized on the basis of RL-
TK level.  The figure shown was a representative of three experiments. 
Insets, expression levels of TIR and TIR mutants as determined by 
immunoblotting. Data represent combined results from three independent 
experiments done in triplicate. Error bars indicate the ± S.E. of the mean. 
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result is consistent with recent modeling studies of the interaction of MyD88 with 
TLR-2 and 4, which suggested that the highly conserved proline residue may not 
participate in the protein-protein interactions of MyD88 with TLRs (Dunne et al., 
2003).  
In contrast to the canonical P200H mutation, the following mutants 
displayed >2.5 fold loss of the dominant negative effect on IL-1β- stimulated 
reporter gene activation as compared to the wild type MyD88 TIR domain (figure 
13B): D171A in helix α-A (T1), triple mutant D195A/R196A/D197A (T2) in Box 2, 
D275A in β-E strand (T4), and double mutant F285A/W286A (T5) in Box 3. The 
result with the F285A/W286A mutant is consistent with the loss of inhibition 
displayed by Box 3-deleted MyD88 TIR domain (figure 11C). All these mutants 
and intact MyD88 TIR domain were expressed at comparable levels in HEK 293T 
cells (insert in figure 13B). Therefore, these mutants were chosen for further 
validation of the functional significance of mutated residues in the MyD88 TIR 
domain.  
 
Inhibition of cytokine production by MyD88-TIR mutants 
We selected IL-1β-induced expression of an endogenous gene that 
encodes the inflammatory cytokine, IL-6, in human fibroblast MRC5 cells for 
testing MyD88 TIR domain mutants. The expression of the IL-6 gene is regulated 
by NFκB and its mobilization by IL-1β is dependent on MyD88 (Akira and Sato, 
2003; Dinarello, 2002; Yamamoto et al., 2004). As shown in figure 14A, upon 
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Figure 14. Inhibition of IL-6 production by MyD88-TIR mutants 
T1, T2, T4 (A) and T5 as compared to nuclear inhibitor SN50 
peptide (B).  
A, IL-1β - induced IL-6 production of MRC-5 cells is specifically inhibited 
by MyD88-TIR mutants. IL-6 production was analyzed with CBA.  
B, IL-1β induced - IL6 production of MRC-5 cells is specifically inhibited by 
nuclear inhibitor peptide SN50. MRC-5 cells pretreated for 30min with 100 
μM SN50 in HBSS or diluent HBSS and then stimulated with 10ng/mL of 
IL-1β for 6 hrs. Data represent combined results from three independent 
experiments done in triplicate. Error bars indicate the ± S.E. of the mean. 
** P<0.01, * P<0.05, by two-sided Student’s t - test. 
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stimulation of MRC5 cells with IL-1β, the inflammatory cytokine IL-6 was 
expressed. To validate its dependence of NFκB and other SRTFs, a nuclear 
import inhibitor, SN50 peptide, was utilized which is able to block NFκB 
responses(Lin et al., 1995).  Treatment with SN50 completely abolished the IL-1 
induced IL-6 production. This expression of endogenous IL-6 gene was 
suppressed 2.5 fold by dominant negative TIR domain of MyD88 (figure 14B). 
The observed degree of inhibition of endogenous IL-6 gene expression is smaller, 
albeit still significant, than the suppression of reporter gene activity by MyD88 
TIR domain observed in HEK 293T cells. The most likely reason for lower degree 
of inhibition is lower transfection efficiency of MRC5 cells that minimizes the 
impact of potential inhibitors on IL-6 expression. Nevertheless, inhibition of IL-
1β-induced IL-6 production was depended on residues D171, D275, 
D195/R196/D197 and F285/W286 because alanine substitutions reduced 
dominant negative effect of wild-type MyD88 TIR domain. These functional 
studies of IL-1β-induced IL-6 production are consistent with reporter gene 
activation (figure 13B). Thus, our first series of mutagenesis experiments 
identified interactive sites within the MyD88 TIR domain responsible for coupling 
IL-1β signaling to NFκB translocation to the nucleus and induction of endogenous 
IL-6 gene. 
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Mutagenesis of full-length MyD88 reveals an interactive site for direct contact 
with IL-1RAcP  
 
It is still unknown which of the interactive sites identified in the MyD88 
TIR domain are responsible for direct contact of MyD88 with the IL-1 receptor 
complex subunit, IL1RAcP, which is indispensable for IL-1β signaling (Radons et 
al., 2002). Theoretically, the MyD88 TIR domain may mediate binding to other 
adaptor proteins also (Dunne et al., 2003). Alternatively, these interactive sites 
within MyD88 could participate in IL-1β-induced oligomerization of MyD88 
through homotypic interactions mediated by its TIR domain.  
To sort out these possibilities, a second series of mutagenesis experiments 
was conducted using a similar strategy. Five selected mutations were engineered 
in a full length MyD88 to allow a comparative analysis of its direct interaction 
with IL1RAcP (Table 1). HEK 293T cells were co-transfected with myc-IL1RAcP 
and AU1-MyD88 or its mutant constructs. We used immunoprecipitation followed 
by immunoblotting to assess the effect of mutated residues on the receptor TIR- 
adaptor TIR interaction. As demonstrated in figure 15, only MyD88 
D195A/R196A/D197A mutant showed loss of binding to IL1RAcP while other 
mutants including MyD88 P200H retained their ability to bind IL1RAcP. This 
result indicates that residues D195A/R196A/D197A may constitute a part of the 
interacting surface of MyD88 and IL1RAcP, while other alanine-substitutions are 
without effect. The selective loss of receptor binding function by MyD88 
D195A/R196A/D197A mutant led us to develop the 3-D docking model of MyD88 
and IL1RAcP and verify the strategic position of these three residues as a main 
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 Table 1 
Information about the MyD88 mutants analyzed in this study 
 
Mutant # Mutation(s) 
M1 MyD88-D171A 
M2 MyD88-P200H 
M3 MyD88-D195A/R196A/D197A 
M4 MyD88-D275A 
M5 MyD88-F285A/W286A 
 
All the MyD88 mutants in this study were generated as indicated under the 
Materials and Methods.  
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Figure 15. Interaction of MyD88 mutants with IL1RAcP.  
HEK 293T cells were transiently transfected with Myc-IL1RAcP (10 µg) and 
full-length MyD88 or its mutants (10 µg). After 24 h, the cells were stimulated 
with 100 ng/ml IL-1β for 5 min, harvested, and immunoprecipitated as 
described under "experimental procedures." Protein samples bound to anti-
myc antibody containing protein A beads were subjected to SDS-PAGE, and 
the immunoprecipitated MyD88 or its mutants were monitored by 
immunoblotting with anti-AU1 antibody (top panel). Expression of MyD88 and 
its mutants (middle panel) and IL1RAcP (bottom panel) was analyzed by 
immunoblotting. 
 
65
interactive site on the surface of the MyD88 TIR domain for its binding to the TIR 
domain of IL1RAcP.  
 
The development of the 3-dimensional docking model of MyD88-IL-1RAcP 
interaction 
 
The 3-D docking model was developed by optimized superposition of two 
mutually interacting TIR domains of MyD88 and IL1RAcP. IL1RAcP TIR domain 
has 33% identity with known 3-dimensional structure of human TLR1 
(1fyvA .pdb); therefore, 1fyvA was used for generating the computing model of 
IL1RAcP (figure 16). 
Negatively charged side of the MyD88-TIR (figure 8 and figure 9B) was 
selected as a possible interface of the molecule. This side contains 
D195/R196/D197 residues that are essential, on the basis of mutagenesis studies 
(figure 15), for MyD88-TIR heterotypic interaction with IL1RAcP-TIR. Then, a 
suitable positively charged site of the IL1RAcP was selected to conduct the 
modeling computation process. This modeling was based on geometry 
optimization by energy minimization followed by molecular dynamic computation 
using the program SANDER (AMBER software package). Ribbon structure was 
developed with the Deep View program while the molecular surface of associated 
proteins was determined by PSSHOW (SYBIL-Tripos software package).  
As shown in figure 17, the separation surface indicates that there is no 
crossing of molecular surfaces and distance between them is within the range of 
0.4 - 4.7 Å while their topology is diverse and contains several deep pockets. 
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395 
IL-1RAcP TIR  --TDETILDGKEYDIYVSYARNAEEEEFVLLTLRGVLENEFGYKLCIFDRDSLPGG
Tlr1 TIR      NIPLEELQRNLQFHAFISYS--GHDSFWVKNELLPNLEKE-GXQICLHERNFVPGK
Cons            . * :  . ::. ::**:  ..:. :*   *   **:* * ::*:.:*: :**  
450 
IL-1RAcP-TIR  IVTDETLSFIQKSRRLLVVLSPNYVLQGTQALLELKAGLENMASRGNINVILVQYK
Tlr1 TIR      SIVENIITCIEKSYKSIFVLSPNFV-QSEWCHYELYFAHHNLFHEGSNSLILILLE
Cons           :.:: :: *:** : :.*****:* *.  .  **  . .*:  .*. .:**:  : 
507 
IL-1RAcP-TIR  AVKETKV----KELKRAKTVLTVIKWKGEKSKYPQGRFWKQLQVAMPVKKSPRRSS
Tlr1 TIR      PIPQYSIPSSYHKLKSLXARRTYLEWPKEKSK--RGLFWANLRAAINIKLTEQAK-
Cons          .: : .: ::**   :  * ::*  ****  :* ** :*:.*: :* : : .  
 
 
Figure 16. Sequence alignment of TIR domain of human IL-1RAcP and 
TLR-1. IL1RAcP TIR domain has 33% identity with known 3D structure of 
human TLR1 (1fyvA.pdb); therefore Pdb file 1fyvA was used to generate the 
computing model of IL1RAcP. 
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Figure 17. The 3-D models of TIR domain of IL1RAcP and MyD88, 
and the docking model of their TIR-TIR interaction.  
A and B, ribbon structure of IL1RAcP TIR domain and MyD88 TIR domain, 
respectively, obtained from homology computation performed using Swiss-
Model and visualized using DeepView (Swiss-PdbViewer). Structural 
features representing the conserved boxes of the MyD88 TIR domain are 
shown in B in yellow (Box 1), purple (Box 2), and blue (Box 3). The 
selected side chains of mutated residues in B and C are marked in green.  
C, ribbon representation of TIR-TIR interaction optimized with SANDER 
energy minimization software (AMBER package). The side chains of 
identified residues on MyD88 TIR (Asp195, Arg196, and Asp197) required for 
direct binding of MyD88 TIR to IL1RAcP TIR as well as the complementary 
residues on EE loop of IL1RAcP TIR are shown in green. The structural 
motifs in A and C are colored as follows: blue, α-helices; red, β-strands; 
and white, loops.  
D, top view of docking superposition presented in molecular surface mode. 
 
68
69
 
 
70
Development of this 3-dimensional model allowed us to verify the contribution of 
the triplet of functionally important residues D195/R196/D197 to the binding 
reaction with IL1RAcP TIR domain. An analysis of the tertiary structure of two 
TIR domains that participate in the docking model indicates that three mutated 
residues (D195/R196/D197) responsible for the loss of MyD88 binding to 
IL1RAcP, are involved in interaction with residues 527-534 of IL1RAcP previously 
identified to play a key role in IL-1β signaling pathway (Radons et al., 2003; 
Radons et al., 2002). Thus, our study identified a complementary site on MyD88 
TIR domain that contributes to its interaction with IL1RAcP TIR domain. We 
therefore postulate that a negatively charged “knob”, partially comprised of the 
BB loop on the surface of MyD88 TIR domain (figure 9B), fits into the positively 
charged lysine patch formed by residues 527, 530, and 532 of the IL1RAcP TIR 
domain previously identified by Radons et al. as essential for IL-1β signaling 
(Radons et al., 2003; Radons et al., 2002).  
 
Homotypic oligomerization: interactive sites  and docking model of MyD88 TIR 
domain 
 
Following IL-1β-induced interaction of IL1RAcP with MyD88, this adaptor 
oligomerizes and interacts with downstream signal transducers (Akira, 2003; 
Akira and Sato, 2003; Yamamoto et al., 2004). Homotypic oligomerization of 
MyD88 due to its forced expression resulted in robust activation of NFκB reporter 
gene activity observed in the absence of IL-1β stimulation (figure 10). This 
receptor- independent effect of ectopically expressed MyD88 oligomers can be 
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abolished by cotransfected MyD88-TIR domain (data not shown). Therefore, we 
examined direct interaction of a full-length MyD88 co-expressed with MyD88 TIR 
domain or its mutants. We co-transfected HEK 293T cells with full length MyD88 
that contained a c-myc epitope tag along with the wild type or mutated TIR 
domain of MyD88 that contained an AU1 epitope tag. As demonstrated in figure 
18, P200H mutant bound to a full-length MyD88 to similar extent as wild-type 
MyD88 TIR domain. However, mutations in Box 2 (D195A/R196A/D197A) and 
Box 3 (βE strand D275A and F285A/W286A) caused a loss of binding to MyD88, 
suggesting that these mutated residues constitute the interactive sites for 
homotypic oligomerization of the MyD88 TIR domain. Thus, interacting site in 
Box 2 comprised of residues D195/R196/D197 has potentially an additional 
function that may encroach on the ability of MyD88 to interact with IL1RAcP. 
However, in a cascade of signaling steps induced by IL-1β, heterotypic 
interaction of IL1RAcP TIR domain with MyD88 TIR domain antecedes 
oligomerization of MyD88. The latter depends on homotypic binding mediated by 
the MyD88 TIR domain. Therefore, the interactive site in Box 3 is likely 
uninvolved in binding of MyD88 to IL1RAcP. Rather, this site participates in 
homotypic MyD88 oligomerization and possibly other transactions involving 
downstream signal transducers. This interpretation is consistent with the loss of 
inhibition of IL-1β-induced signaling by MyD88 TIR domain upon truncation of its 
COOH-terminal segment that contains Box 3.  
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Figure 18. Homotypic interaction of the TIR domain of MyD88 with full-
length MyD88. The HEK 293T cells were transiently transfected with c-Myc-
tagged full-length MyD88 (5 µg) and AU1-tagged MyD88-TIR (5 µg) or AU1-
tagged MyD88-TIR mutants (5 µg). After 24 h, the cells were harvested and 
immunoprecipitated as described under "Experimental Procedures." Protein 
samples bound to anti-AU1 antibody containing Protein A beads were subjected 
to SDS-PAGE and immunoprecipitated. MyD88-TIR or its mutants were detected 
with anti-myc antibody (top panel). Expression of MyD88-TIR and MyD88-TIR 
mutants (middle panel) or MyD88 (bottom panel) was analyzed by 
immunoblotting with indicated antibodies. 
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On the basis of these studies, a 3-dimensional docking model of MyD88 
TIR homotypic interaction was generated with geometry optimization by energy 
minimization followed by molecular dynamics (AMBER package). Ribbon 
structures were developed with the Deep View program. Development of this 
docking model allowed us to verify the contribution of the mutated residues. As 
presented in figure 19, within this model of the homotypic interaction of MyD88 
TIR domain, besides D195R196D197 (BB loop) and D171 that bind to Box 3, 
especially to K291, another pair of interacting residues was suggested, D275 on 
the one TIR domain and K231 at the other. 
 
Discussion 
 In this combined mutagenesis and 3-dimensional modeling study, we 
identified key residues in the MyD88 TIR domain that are responsible for its 
heterotypic interaction with IL1RAcP. In addition, we identified interactive sites 
for homotypic oligomerization of MyD88. These protein-protein interactions 
evoked by IL-1β are essential for its signaling to the nucleus mediated by NFκB 
and other proinflammatory stress responsive transcription factors. Mutations 
identified on the interacting surface of the MyD88 TIR domain are functionally 
important because they interfere with the induction of the endogenous gene that 
encodes IL-6. This inflammatory cytokine, along with IL-1β, is responsible for 
cardinal signs of systemic inflammation: fever, leukocytosis, thrombocytosis, 
acute phase protein response, and tissue injury (Dinarello, 1996; Dinarello, 2002). 
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Figure 19. MyD88 TIR–TIR docking model. This homotypic interaction 
was depicted in ribbon representation optimized with SANDER energy 
minimization software (AMBER package). The selected side chains of mutated 
residues are marked in green In this homotypic interaction, besides 
D195R196D197 (BB loop) and D171 that bind to Box 3, especially to K291. 
Another pair of potential interacting residues was found: D275 at the one TIR 
and K231 at the other. 
75
The development of the docking 3-dimensional model of MyD88-IL1RAcP binding, 
in which a cluster of highly charged residues in Box 2 plays a key role, reaffirms 
their strategic role in contacting a complementary site on IL1RAcP TIR domain. 
This site is comprised of several positively charged residues identified previously 
in EE loop residues 527-534 (Radons et al., 2003; Radons et al., 2002). Thus, it 
is not surprising that the invariant proline 200 is inconsequential for MyD88-
ILRAcP interaction. However, mutation of the canonical proline to histidine in 
TLR-4, which abolishes its signaling by LPS (Poltorak et al., 1998), indicates that 
different ligands and their cognate TLRs utilize MyD88 in structurally distinct 
ways. In addition to TLR-4, Proline to Histidine mutation attenuated signaling 
mediated by TLR-2, MAL, and IL1RAcP (Horng et al., 2001; Poltorak et al., 1998; 
Radons et al., 2002). We interpret the latter result as indicative of the invariant 
proline playing a significant role in reshaping the EE loop in IL1RAcP or in 
interactions with the TIR domain of IL-1RI or with signaling molecules other than 
MyD88. Further mapping of the MyD88 surface will expand our understanding of 
its role in integrating signals derived from a variety of Toll-like receptors.  
 
Summary and conclusions 
1. MyD88 is the essential adaptor protein that integrates and transduces 
intracellular signals generated by multiple Toll-like receptors including the 
receptor complex for IL-1β, a key inflammatory cytokine. As reviewed in Chapter 
1, MyD88 plays a key role in IL-1β signaling. This essential role is supported by 
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other studies with MyD88 -deficient mice which demonstrated the lack of 
signaling in response to ligands such as IL-1, IL-18, peptidoglycan, LPS, and 
CpG-DNA (Adachi et al., 1998; Kawai et al., 1999). 
 
2.  MyD88 interacts with the IL-1β receptor complex via the Toll/IL1 receptor 
(TIR) domain.  This interaction is a critical step in IL-1β evoked signaling to the 
nucleus. Previous studies suggested the involvement of direct binding between 
TIR domain of IL1RAcP and TIR domain of MyD88, as well as homotypic 
oligomerization of MyD88 via TIR domains (Radons et al., 2003; Radons et al., 
2002). 
 
3. I conducted structure-function studies that helped to define the MyD88 
TIR domain binding sites involved in heterotypic interaction with IL1RAcP. The 
MyD88 TIR domain, employed as a dominant negative inhibitor of IL-1β signaling 
to screen MyD88 TIR mutants, lost its suppressing activity upon the truncation of 
Box 3. Accordingly, mutations of Box 3 residues 285–286 reversed the dominant 
negative effect of the MyD88 TIR domain on IL-1β-induced and NFκB-dependent 
reporter gene activity and IL-6 production. Moreover, mutations of residues 171 
in helix α-A, 195–197 in Box 2, and 275 in β-E strand had similar functional 
effects.  
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4.      Strikingly, based on co-immunoprecipitation studies, only mutations of 
residues 195–197 eliminated the direct TIR-TIR interaction of MyD88 and IL-1 
receptor accessory protein (IL1RAcP), whereas substitution of neighboring 
canonical Pro200 by His in MyD88 TIR domain was without effect. 
 
5. Using NFκB reporter gene activation, cytokine production, and co-
immunoprecipitation analysis, I demonstrated that homotypic MyD88 
oligomerization via the TIR domain interaction is ablated by mutations in Box 2 
and Box 3 of the TIR domain. 
  
6. The above results provided essential structural and functional information 
for development of a docking 3-dimensional model of MyD88-IL1RAcP interaction, 
verifying a key role of a cluster of highly charged residues in Box 2. This model is 
consistent with previous studies, which showed that several positively charged 
residues(a.a.527-534) within the EE loop of IL1RAcP are the sites responsible for 
IL1RAcP/MyD88 interaction (Radons et al., 2003; Radons et al., 2002). According 
to our 3-dimensional docking model, these conserved residues of IL1RAcP are 
indeed in direct contact with  the highly charged residues 195-197 in Box 2 of 
MyD88 TIR identified in the mutagenesis and co-immunoprecipitation 
experiments. 
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7.  Based on the co-immunoprecipitation studies of MyD88 TIR domain 
mutants, a second docking 3-dimensional model was developed to define MyD88 
homotypic interaction via its TIR domain. This model points to the essential role 
of several amino acid residues: D195R196D197 (BB loop) and D171 of one TIR 
domain were in close proximity to Box 3, especially K291, of its counterpart.  
Another pair of potential interacting residues was D275 at the one TIR domain 
and K231 at the other. 
 
In conclusion, my studies based on biochemical characterization and 
computational modeling analysis led to the establishment of the first 3-
dimensional docking models of TIR-TIR interaction between MyD88 and IL1RAcP 
and of TIR-TIR homotypic oligomerization of MyD88 induced in IL-1β stimulated 
cells. This new information on the fundamental mechanisms of how MyD88, the 
key relay station in IL-1β signaling pathway, interacts with IL-1R/IL1RAcP 
receptor complex, provides a platform for further comparative analysis of MyD88 
interaction with other members of Toll-like receptors family. Finally, the results 
presented here are expected to contribute to the development of therapeutic 
agents that interfere with IL-1β-induced proinflammatory signaling by disrupting 
the TIR-TIR interactions as defined in these studies.  
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Future directions 
In this study, I defined the MyD88 TIR domain binding sites involved in 
heterotypic interaction with IL1RAcP as well as in homotypic interaction. The 3-
dimensional docking models of TIR-TIR interaction between MyD88 and IL1RAcP 
and of TIR-TIR homotypic oligomerization of MyD88 provided fundamental 
information regarding the interaction between MyD88 and members of the Toll-
like receptor family. Further characterization of interactive sites of MyD88 with 
other TLRs will give more insight regarding how this versatile adaptor protein 
mediates different Toll-like receptor signaling pathways to achieve distinct 
signaling outcomes and may eventually reveal the physiological significance of 
TIR-TIR interaction in inflammation. Comparative analysis of other TIR domain 
containing adaptors based on the characterization of MyD88 in this study will aid 
on better understanding of how different adaptor usage by different Toll-like 
receptors lead to distinct signaling outcomes. The docking studies also 
established an excellent model for the development of therapeutic agents that 
can specifically interfere with IL-1 signaling by disrupting the TIR-TIR interaction. 
 
Comparative analysis of heterotypic interactions of MyD88 and TLRs  
The MyD88 TIR domain was employed as a dominant negative inhibitor of 
IL-1β signaling to screen MyD88 TIR mutants. The truncation mutants and point-
mutations substituted with alanine were analyzed for IL-1β-induced NFκB 
reporter gene activation, cytokine production, and direct binding with IL1RAcP. 
80
The TIR domain of MyD88 lost its suppressing activity on IL-1β-induced and 
NFκB-dependent reporter gene activity and IL-6 production following truncation 
of Box 3 and mutations of Box 3 residues 285–286. Moreover, mutations of 
residues 171 in helix α-A, 195–197 in Box 2, and 275 in β-E strand had similar 
functional effects.  
For IL-1R/TLR members other than IL-1R, recruitment of MyD88 may 
occur at different binding sites of the MyD88 TIR domain. Thus, the functional 
impact of these mutations on other Toll-like receptor signaling pathways remains 
an open question. The significance of the interactive sites of the MyD88 TIR 
domain in LPS-induced TLR-4 signaling pathway is of particular interest. Although 
it is well established that the binding of LPS from Gram-negative bacteria to TLR-
4 on macrophages can induce production of pro-inflammatory cytokines (e.g. IL-
1) and provoke the acute phase response to infection (Dunne and O'Neill, 2003),  
the mechanism of the TIR-TIR interaction between TLR-4 and MyD88 is 
unknown. In previous computational docking studies, MyD88 was predicted to 
bind with a surface composed with its AA- and DD-loop to the CD-loop on TLR-4, 
which is located on the other side of the receptor, opposite its BB-loop (Dunne et 
al., 2003). Using NFκB reporter gene activation assay and production of IL-6 as 
described in this thesis, mutants corresponding to AA- and DD- loop are of 
potential value for testing their involvement in MyD88-TLR-4 interaction. 
Substitution of D171 in the TIR domain of MyD88 led to the loss of IL-1β- 
induced NFκB activation and IL-6 production. Comparative analysis of heterotypic 
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interactions of MyD88 and TLRs will give some insight into whether distinct 
interactive surfaces of MyD88 are responsible for different TLR signaling 
cascades. Our model will serve as a matrix to determine how MyD88 can mediate 
multiple Toll-like receptor signaling pathways. 
 
Developing cell-penetrating peptide/protein as therapeutic agents  
The 3-dimensional docking models of TIR-TIR interaction between MyD88 
and   IL1RAcP and of TIR-TIR homotypic oligomerization of MyD88 provide an 
excellent platform for the development of therapeutic agents that interfere with 
IL-1 signaling by disrupting the TIR-TIR interaction. To counteract the effect of 
IL-1 in inflammatory responses, IL-1 blockade with the recombinant form of the 
naturally occurring IL-1Ra has been widely accepted (Dinarello, 2004). An 
alternative strategy is block the downstream signaling pathway by directly 
targeting key signaling molecules such as MyD88. Therefore, this study may help 
to develop effective therapeutic agents to treat inflammation-related diseases 
driven by IL-1. 
Bartfai et al. reported that a low molecular weight TIR mimic, 
hydrocinnamoyl-L-valyl pyrrolidine, modeled on a tripeptide sequence of the BB-
loop [(F/Y)-(V/L/I)-(P/G)], can block the IL-1β - induced phosphorylation of the 
mitogen-activated protein kinase p38 in vitro. In vivo, a mouse fever model 
induced by IL-1β is also effectively attenuated by giving intraperitoneal injection 
of 200 mg/kg of this compound (Bartfai et al., 2003). Pilot experiments of 
82
designing anti-inflammatory cell-penetrating peptide based on TIR-TIR 
interaction were conducted in our laboratory using conserved structure elements 
such as the BB loop and box 3 of the TIR domain derived from MyD88, TLR-4, 
and IL-1R; however, the solubility and functionality were limited. Further 
experiments to optimize the peptide solubility are needed for proper assessment 
of their functionality in context of the IL-1β - induced signaling via IL-1R complex 
as well as LPS-induced signaling via TLR-4.  
The TIR domain of MyD88 has been shown to be a potent dominant 
negative inhibitor of IL-1β – induced NFκB activation and IL-6 production (figure 
9 and figure 10). In combination with the cell-penetrating peptide/protein 
transduction technique developed in our laboratory (Hawiger, 1999; Jo et al., 
2005; Lin et al., 1995), recombinant protein comprising MyD88 TIR domain is 
engineered.  The TIR domain of MyD88 in the context of a cell-penetrating motif 
derived from the hydrophobic region of the signal sequence of Kaposi fibroblast 
growth factor (K-FGF) has been designed and purified in a prokaryotic expression 
system of E. coli. However, the expressed fusion protein formed inclusion bodies 
and, therefore, had been limited in the functional evaluations (data not shown).  
Further experiments are needed to improve the solubility of fusion protein so 
that it can be tested for inhibition of IL-1β–induced or lipopolysaccharide-induced 
NFκB nuclear translocation and cytokine production in animal models described 
previously (Yan Liu et al., 2000). 
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In summary, the new information on the fundamental mechanism of 
MyD88 function in multiple IL-1R/TLR signaling pathways will provide a 
comprehensive understanding of the inflammatory responses mediated by TIR-
TIR interactions. These results will help in the development of therapeutic agents 
that specifically interfere with MyD88-mediated proinflammatory signaling by 
disrupting the TIR-TIR interactions as defined in these studies.  
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CHAPTER III 
 
GENE EXPRESSION PROFILING IN RESPONSE TO PROINFLAMMATORY 
AGONISTS 
 
 
Synopsis 
 
Inflammation is the major mechanism of cardiac, pulmonary and vascular 
diseases, the main cause of mortality in the United States. The identification of 
genes involved in inflammation and the characterization of their functions will 
help to develop effective treatment for a wide variety of diseases. Genome-wide 
expression profiling using high-density DNA microarrays provides an 
unprecedented opportunity for mechanistic studies of inflammation. Animal 
models of systemic inflammation induced by staphylococcal enterotoxin B (SEB) 
and lipopolysaccharide (LPS) were used to study genome-wide transcriptional 
response.  Animal models of systemic inflammation induced by staphylococcal 
enterotoxin B (SEB) and lipopolysaccharide (LPS) were used to study genome-
wide transcriptional response.  
In vivo treatment with SEB induced 134 and 209 genes in spleen cells and 
T lymphocytes, respectively. Upregulation of these genes was inhibited by 
blocking NFκB signaling with a cell-penetrating nuclear import inhibitor cSN50 
peptide or the IκBαΔN transgene. In vivo treatment of LPS induced upregulation 
of 1296 genes and downregulation of 1551 genes in the liver and 
correspondingly, 1109 and 402 genes in the spleen. The genome-wide response 
85
to LPS was ablated in TLR-4-deficent C3H/HeJ mice. The cSN50 peptide blocked 
547 LPS-inducible and 669 LPS-downregulated genes in the liver, and 105 LPS-
inducible and 230 LPS-suppressed genes in the spleen. Thus, nuclear import of 
NFκB and other stress-responsive transcription factors plays an important role in 
genome-wide response to microbial inducers of inflammation. 
 
 
Gene expression profiling in response to  
staphylococcal enterotoxin B (SEB) 
 
An animal model of systemic inflammation induced by staphylococcal 
enterotoxin B (SEB), an agonist for T lymphocytes, was used. In this model, 
inhibition of nuclear import of NFκB and other stress responsive transcription 
factors (SRTFs) by cell-penetrating peptide cSN50 has been previously shown to 
prevent the increase in proinflammatory cytokines and chemokines. Moreover, 
the mortality induced by SEB in mice was reduced by 87% (Liu et al., 2004b). 
Here, we analyzed the gene expression profile of spleen cells and T lymphocytes 
after SEB administration. We identified 134 and 209 SEB-activated genes in the 
spleen cells and T lymphocytes, respectively. In T lymphocytes, 182 out of 209 
activated genes were suppressed upon the treatment with a cell-penetrating 
peptide cSN50 via intravenous injection. The same treatment abolished the 
activation of all 134 genes in the spleen. These protective effects of cSN50 were 
fully recapitulated in the studies of transgenic mice expressing a mutant form of 
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IκBα which constitutively inhibits NFκB translocation into the nucleus. We 
concluded that SEB-induced genome-wide transcriptional activation in T 
lymphocytes is mediated by nuclear import of NFκB and other stress-responsive 
transcription factors. These findings provide the first evidence that genome–wide 
transcriptional activation during systemic inflammatory response evoked by SEB 
in T lymphocytes is dependent of nuclear import of NFκB and other SRTFs. 
 
Systemic inflammation induced by staphylococcal enterotoxin B   
SEB is produced by Staphylococcus aureus and causes various types of 
human diseases, including gastroenteritis resulting from consumption of 
contaminated food and non-menstrual toxic shock syndrome (NMTSS) (Balaban 
and Rasooly, 2000; Dinges et al., 2000). In addition, SEB is a potent 
superantigen that stimulates non-specific T-cell proliferation. SEB binds to the Vβ 
chain (Vβ7, Vβ8 and Vβ11) of the T cell receptor and major histocompatibility 
complex class II (MHC II) on dendritic cells or macrophages and forms an 
intercellular "synapse" (Bhardwaj et al., 1993; Seth et al., 1994; White et al., 
1989). SEB stimulation leads to a cytokine “storm” from mainly T cells, with 
massive  production of inflammatory cytokines including TNF-α, interferon γ(IFN-
γ), interleukin (IL)-1β, IL-2, and IL-6, which leads to massive vascular injury, 
organ failure, and lethal respiratory distress syndrome or toxic shock (Balaban 
and Rasooly, 2000; Dinges et al., 2000; Madsen, 2001; Mattix et al., 1995).  
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The genes that encode inflammatory cytokines are under the control of 
SRTFs, including nuclear factor kappa B (NFκB), activator protein-1 (AP-1), 
nuclear factor of activated T cells (NFAT), and signal transducer and activator of 
transcription 1 (STAT1) (Hawiger, 2001). After mobilization to the nucleus, SRTFs 
stimulate genome-wide transcriptional activation of  multiple genes encoding 
cytokines, chemokines, and other mediators of inflammation (Goldfeld et al., 
1993; Sica et al., 1997; Teague et al., 1999; Tsai et al., 1996). We hypothesize 
that by combining genome-wide expression profile analysis with inhibition of 
SRTF cytoplasmic/nuclear translocation, we will be able to develop a global view 
of SEB-induced signaling to the nucleus via SRTFs and may identify new genes 
related to inflammatory responses. 
To test this hypothesis, we applied cell-penetrating cSN50 peptides to 
inhibit nuclear import of SRTFs in T cells stimulated by SEB (Lin et al., 1995; Yan 
Liu et al., 2000). The inhibitors of nuclear import used in the animal model for 
SEB toxicity contain a cyclized form of the nuclear localization signal (NLS) from 
the p50/NFκB1 subunit of NFκB and membrane-translocating motif (MTM) from 
the signal sequence hydrophobic segment of fibroblast growth factor 4 (Yan Liu 
et al., 2000). MTM enables peptide or protein cargoes to cross the plasma 
membrane of multiple cell types in various organs via a receptor/transporter-
independent mechanism (Hawiger, 1999; Jo et al., 2005; Jo et al., 2001; 
Torgerson et al., 1998; Veach et al., 2004; Yan Liu et al., 2000). These cell-
penetrating peptides carrying NLS have been shown to simultaneously block the 
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nuclear import of multiple SRTFs by targeting Rch1/importin  α/karyopherin-α2 in 
a Jurkat T cell line (Torgerson et al., 1998). Thus, we used cSN50-mediated 
inhibition of SRTFs as a novel platform to investigate the role of SRTFs nuclear 
import in the global regulation of inflammation related genes in T lymphocytes, 
the essential target for SEB-induced toxicity (Aoki et al., 1995; Marrack et al., 
1990). 
 
cSN50 blocks the cytokine storm induced by superantigen SEB in vivo 
Most of the lethal effects of SEB have been attributed to superantigenicity 
and subsequent T-cell proliferation with massive inflammatory cytokine release. 
BALB/c mice with both I-A and I-E major histocompatibility complex class II 
isotypes of the H-2d haplotype are 50 times more susceptible to SEB than the 
C57BL/6 strain (Taub et al., 1992). Thus, BALB/c mice were chosen to study the 
deleterious effects of SEB-induced cytokine “storm”. In this murine model, 
administration of SEB via an intravenous route evokes massive production of 
cytokines which mediates the acute systemic inflammatory disorder. Under this 
condition, cytokine “storm” by SEB treatment does not lead to lethality, unless 
mice are either genetically manipulated (Anderson and Tary-Lehmann, 2001; 
Chen et al., 1994; Yeung et al., 1996) or previously sensitized with D-
galactosamine or endotoxin (Liu et al., 2004b). Injection of 150ug of SEB into 
BALB/c mice caused a rapid rise in plasma TNF-α and IL-2 levels that peaked 
around 1hr, followed by a more progressive increase in IFN-γ (figure 20A). 
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Figure 20. Cytokine production and genome-wide expression 
profiling in the spleen induced by SEB and regulated by nuclear 
import inhibitor CSN50 or IκBαΔN transgene.  
A, Suppression of SEB-Induced cytokine expression by nuclear import 
inhibitor cSN50 (significance was assessed by two-way AVOVA). 
B, Suppression of cytokine expression in IκBαΔN transgenic mice which 
bear a dominant negative inhibitor of NFκB in T-lymphocytes. Cytokine 
levels were measured by CBA as described in experimental procedures. 
Data shown here represent Mean ± SE from at least 3 mice in each group. 
P value was calculated using two-way Anova with Bonferroni post-test.  
C, Venn diagram of SEB-induced gene expression in whole spleen 
regulated by nuclear import inhibitor.  
D, Venn diagram of regulated gene expression in spleen of IκBαΔN 
transgenic mice.  Only genes that showed at least 2-fold induction or 
suppression with a minimum of 66% reproducibility as compared with 
control samples are included in the analysis. Each of these spots has a 
coefficient of variance(COV) less than or equal to 30%. 
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Administration of cSN50, before and after SEB exposure, suppressed the 
induction of inflammatory cytokines. Plasma levels of inflammatory cytokines 
including TNF-α, IFN-γ, and IL-2 were significantly decreased. This inhibition of 
cytokine production was fully recapitulated in IκBαΔN transgenic mice which bear 
a dominant negative inhibitor of NFκB  in T lymphocytes in the C57BL/6 
background (Liu et al., 2004b) (figure 20B). Therefore, whole spleen and splenic 
T cells were isolated from the mice to study further the regulation of SEB-
induced genes. 
 
Gene expression in the whole spleen correlates with SEB-induced toxic shock 
syndrome  
 
SEB induces a “storm” of inflammatory cytokines, including TNF-α and 
IFN-γ, which contribute to the widespread systemic damage, multiorgan failure 
and even shock and significant morbidity. To elucidate the gene expression 
regulation underlining these events, we performed microarray profiling of whole 
mouse spleen harvested from BALB/c mice challenged with SEB and not treated 
or treated with cSN50 peptide. The experimental design is described in the 
Materials and Methods. The microarray included 22,172 cDNAs from the National 
Institute on Aging (NIA) set. 
The examination of the overall gene expression patterns indicates that 
134 genes became strongly up-regulated while very few (3 genes) were 
downregulated (figure 20C). Strikingly, all 134 activated genes, as based on an 
over2-fold increase in their expression in SEB-stimulated mice, were blocked in 
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mice treated with nuclear import inhibitor, cSN50 peptide (figure 20C). Since 
cSN50 has been previously shown to target nuclear import complex shuttling 
SRTFs to the nucleus, it is reasonable to interpret that these transactivators are 
required for SEB-induced gene expression in T lymphocytes in vivo. This notion is 
further supported by the analysis of gene expression in whole spleen of IκBαΔN 
transgenic mice. IκBαΔN is the dominant negative mutant of IκBα and the 
transgene leads to inhibition of NFκB nuclear translocation. The SEB-induced 
genome-wide activation is completely ablated in SEB treated transgenic mice as 
compared to wild-type animals. Our data indicate that NFκB is the essential 
transcription factor among all SRTFs for signaling to the nucleus and genome-
wide activation in response to SEB in vivo. 
We performed further analysis and functional clustering studies of SEB- 
upregulated genes. All of the information regarding this microarray analysis is 
available as supplementary data on the VUSR website 
(http://array.mc.vanderbilt.edu/). The majority of the SEB-activated genes could 
be classified by grouping them into functional groups encompassing metabolism, 
including protein metabolism and nucleobase, nucleoside, nucleotide and nucleic 
acid metabolism, response to stimulus, cell cycle, transcriptional regulation and 
structural molecules.  
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Gene expression in spleen T cells correlates with SEB-induced toxic shock 
syndrome 
 
T cells constitute one third of the total spleen cells and are the main 
source for cytokines responsible for SEB toxicosis and toxic shock. SEB-induced 
lethal shock is T-cell dependent in mice models with or without co-administration 
of D-Gal (Anderson and Tary-Lehmann, 2001). Upon SEB stimulation, 
proliferation of T cells bearing Vβ8 and CD69 peaks at 18-24 hrs in both spleen 
and lymphnodes, at 48-72hrs the percentage of this T cell population is back to 
normal as a result of apoptosis (Liu and Hawiger, unpublished data). To address 
the SEB-induced gene expression regulation in T cells, we performed a 
comprehensive analysis of gene expression in T cells isolated from the spleen of 
BALB/c mice 24hrs after SEB injection.  
The overall patterns (figure 21A) demonstrated that 209 genes became 
strongly up-regulated while 3 genes were downregulated. Boolean operation 
showed in T cells, which are the main cell population responsible for SEB 
toxicosis, 45% (97 out of 209) of the SEB-induced genes were also activated in 
the spleen. This subset of genes represent 75% (97 out of 134) of the whole 
spleen SEB-inducible genes (figure 21B). Consistent with the analysis in the 
whole spleen, most of the upregulated genes in T cells (182 out of 209) were 
inhibited by cSN50 treatment (figure 21A), further confirming the essential role 
of SRTFs nuclear import in SEB-induced transcriptional regulation. Moreover, the 
effectiveness of cSN50 as an inhibitor of the SEB-mediated response is based on 
transcriptional “silencing” of inflammatory response in T cells. 
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Figure 21. SEB-induced gene expression profile in spleen T 
cells. 
A, Venn diagrams of SEB-induced (left) and SEB-suppressed (right) 
genes in T lymphocytes of mice treated with and without nuclear 
import inhibitor peptide cSN50 in vivo.  
B, Venn diagram of SEB-induced genes in whole spleen and T 
lymphocytes. Boolean operation showed 45% (97 out of 209) of 
the SEB-induced genes in T cells are also activated in the spleen, 
and this subset of common genes represents 75% (97 out of 134) 
of the whole spleen SEB-inducible genes.  
C, Venn diagram of SEB-induced, nuclear import-dependent genes 
in whole spleen and T lymphocytes. Only genes that showed at 
least 2-fold differences at a minimum of 66% of replicates as 
compared with control are included in the analysis.  Each of these 
spots has a coefficient of variance (COV) less than or equal to 30%. 
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The 182 genes which were inhibited by cSN50 were then classified into 
functional groups. All of the data are available as supplementary material on the 
VMSR website (http://array.mc.vanderbilt.edu/). Three-fourth of the upregulated 
genes were functionally classified by metabolism, including protein metabolism 
and nucleobase, nucleoside, nucleotide and nucleic acid metabolism. Genes 
linked to transcription regulation, response to stimulus, and cell cycle are also 
significantly represented. Thus, our study provided new in vivo evidence of the 
dependence of genome-wide transcriptional regulation on SRTFs nuclear import 
in response to superantigen SEB. 
 
Gene expression profiling in response to LPS 
Systemic inflammation caused by endotoxic LPS, the most potent 
proinflammatory pathogen-derived ligand that interacts with TLRs on monocytes, 
macrophages, dendritic cells, and B cells, leads to the induction of a robust 
production of cytokines and chemokines. These inflammatory mediators include 
TNF-α, IL-1, IL-6, IL-8, IL-10, IL-12, and IL-18  (Liu et al., 2004a). In addition, 
other chemokines (e.g. MIP-1, macrophage inflammatory protein-1), 
inflammatory prostanoids, leukotrienes, and reactive oxygen and nitrogen 
intermediates are produced upon LPS stimulation (Hawiger, 2001). The robust 
activation of the mouse transcriptisome is primarily dependent on the interaction 
of LPS with Toll-like receptor (TLR-4) (see detailed description in chapter I). 
Previous studies from our laboratory have demonstrated that the LPS-induced 
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cytokine and chemokine production is blocked by the cell-penetrating cSN50 
peptide inhibitor of nuclear import (Liu et al., 2004a). The cSN50 peptide 
administration can also prevent inflammation-associated liver apoptosis, DIC, and 
promote increased survival of LPS-challenged mice from 7% to 71%. Therefore, 
we reasoned that genome-wide transcription activation is dependent on nuclear 
import of SRTFs including NFκB, AP-1, STAT1 and NFAT (Torgerson et al., 1998).   
 The LPS-evoked inflammatory response is dependent on expression of 
TLR-4 in phagocytes (macrophages) which are abundantly present in the liver 
and known as Kupffer cells (Liu et al., 2004a). In the spleen, the most abundant 
cells that respond to LPS are B lymphocytes. They express not only TLR-4 and 
TLR-3 but also another member of TLR family denoted RP105 which can 
potentially participate in the response to LPS (Kimoto et al., 2003; Kusumoto and 
Miyake, 2002; Miyake et al., 2000; Ogata et al., 2000). In response to a high 
dose of LPS (40 mg/kg), mice produce robustly inflammatory 
cytokines/chemokines and succumb within 72 hours (Liu et al., 2004a). We 
conducted an extensive analysis of genes induced by LPS (40 mg/kg) in TLR-4-
sufficient C3H/HeN and TLR-4-deficient C3H/HeJ mice. Genome-wide expression 
profiles in the liver wherein Kupffer cells are targeted, and the spleen wherein B 
lymphocytes are predominantly targeted, were analyzed and compared between 
C3H/HeN and TLR-4-deficient C3H/HeJ mice. 
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The role of Toll-like receptor 4 (TLR4) in LPS-induced inflammatory response in 
vivo 
 
A systemic inflammatory response in C3H/HeN mice was induced by 
intraperitoneal injection of 40 mg/kg LPS. RNA was purified from the liver or 
spleen harvested at 24 hours post-injection. RNA samples were used to 
interrogate a high-density Affymetrix oligonucleotide array containing over 
39,000 transcripts, approximate the size of the protein coding capacity of the 
mouse genome. As depicted in figure 22, LPS induced upregulation of 1296 
genes and downregulation of 1551 genes in the liver. Thus, a genome-wide 
analysis of LPS induced gene alteration documents an adaptation to endotoxic 
challenge involving about 10% of the mouse genome. Metabolic adjustments, 
innate immunity components, and adaptive immunity mediators are well 
represented in the LPS-regulated genes. In the spleen, LPS-induced 
transcriptional response involved upregulation of 1109 genes and suppression of 
402 genes. This genome-wide transcriptional regulation by LPS is dependent 
almost entirely on LPS-induced signaling through TLR-4. Surprisingly, induction 
of 1109 genes and suppression of 402 genes in the spleen is also dependent on 
TLR-4 without significant usage of alternative signaling pathways evoked by LPS 
interaction with TLR-3 or RP105. Thus, TLR-4 plays the essential role in LPS-
induced systemic inflammatory response involving primarily macrophages in the 
liver and B lymphocytes in the spleen. The lack of genome response in C3H/HeJ 
mice with defective TLR-4 signaling indicates that over 98% of the genome-wide 
adaptation to LPS in vivo is TLR-4-dependent.  
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Figure 22. TLR-4 mutation in C3H/HeJ mice render the LPS 
response in gene profiling compare with C3H/HeN mice.  
A, LPS-induced gene activation in spleen and liver of C3H/HeN mice is 
abolished by TLR-4 deficiency in C3H/HeJ mice.  
B, Venn diagrams of LPS-inducible genes in liver and spleen, showing over 
98% of the genome-wide transcription activation is TLR-4-dependent.  
C, LPS-induced gene suppression in spleen and liver of C3H/HeN mice is 
abolished by the deficient TLR-4 gene in C3H/HeJ mice. D, Venn diagrams 
of LPS-suppressible genes in liver and spleen, demonstrating over 98% of 
transcription suppression is TLR4-dependent. 
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The role of SRTFs in LPS-induced inflammatory response in vivo 
Signaling to the nucleus mediated by NFκB and other SRTFs play a 
significant role in transcriptional regulation evoked by LPS (Hawiger, 2001).  As 
demonstrated in figure 23, nuclear import inhibitor, cSN50, suppressed almost 
50% (547 out of 1296) of LPS-inducible genes in the liver and about 10% (105 
out of 1109) in the spleen. Among LPS-suppressed genes, cSN50 administration 
blocked the suppression of almost 45% of genes (669 out of 1551) in the liver 
and more than 50% (230 out of 402) in the spleen. A reciprocal relationship is 
observed between the response of metabolic genes (carbohydrate, lipid, fatty 
acid and steroid metabolism) and intracellular signaling genes (genes related to 
cytokine/chemokine pathway, and genes involving pre-mRNA modification and 
mRNA splicing). Genes involved in intracellular signaling are more prominently 
presented in the LPS-induced pool while genes involved in metabolism are 
predominant in the LPS-suppressed pool. The adjustment of metabolic gene 
expression in the liver is consistent with the observation that systemic 
inflammation is often accompanied by alterations of triglyceride-rich lipoproteins, 
high-density lipoproteins cholesterol, and cholesterol transport (Khovidhunkit et 
al., 2000).  
This hitherto unreported comprehensive analysis of the nuclear import-
dependent genome response to a proinflammatory agonist is consistent with our 
previous data demonstrating the highly protective effect of cell-penetrating 
nuclear import inhibitor in a murine model of LPS-induced lethal inflammation, 
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Figure 23. Genome-wide expression profiling in the liver and spleen 
induced by LPS and regulated by nuclear import inhibitor CSN50.  
A, Venn diagram of LPS-induced genes in the liver and the spleen regulated by 
nuclear import inhibitor.  
B, Venn diagram of LPS-suppressed genes in the liver and the spleen regulated 
by nuclear import inhibitor. Only genes that showed at least 2-fold induction or 
suppression with a minimum of 66% reproducibility as compared with control 
samples are included in the analysis. Each of these spots has a coefficient of 
variance (COV) less than or equal to 30%. 
104
apoptosis, microvascular thrombosis, and hemorrhagic necrosis (Liu et al., 
2004a). The survival rate of mice challenged with LPS and D-galactosamine was 
increased by 10 fold (from 7% to 71%) in mice treated with the nuclear import 
inhibitor, cSN50 (Liu et al., 2004a).  
 
Discussion 
Inflammation is the major mechanism of diseases caused by biological, 
chemical, and physical agents. Cumulatively, the morbidity and mortality due to 
inflammation-mediated diseases including coronary heart diseases, sepsis, and 
acute respiratory distress syndrome far exceeds that caused by cancer, 
neurodegeneration, and inborn errors of metabolism. Signaling to the nucleus 
induced by proinflammatory agonists is responsible for an extensive 
reprogramming of the genome. The “inflamed” genes encode mediators and 
suppressors of inflammation and apoptosis (Vanderbilt Program on Functional 
Genomics of Inflammation website, http://www.inflamedgene.org/). This burst of 
transcriptional activity can be suppressed by cell-penetrating peptide inhibitor of 
nuclear import validating a new “nuclear paradigm of inflammation” (Hawiger, 
2001). The nuclear import inhibitor (cSN50) is effective in animal models of 
systemic inflammation triggered by pathogen-derived endotoxin LPS and 
staphylococcal enterotoxin B (a class B agent) (Liu et al., 2004a; Liu et al., 
2004b). 
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Detailed information of the genes described in this chapter can be found 
on VMSR website (http://array.mc.vanderbilt.edu/). Selected genes have been 
verified by real-time RT-PCR and the results are consistent with the microarray 
study (data not shown). A few genes from the list of nuclear import-dependent, 
LPS-inducible genes in the liver of C3H/HeN mice were chosen for further study 
for their role in inflammation in mice deficient in these genes. The lessons drawn 
from our analysis will be extremely useful for the conceptual development of new 
therapeutic approaches toward systemic and organ-based inflammatory diseases.  
 
Summary and conclusions 
Inflammation is the major mechanism of cardiac, pulmonary and vascular 
disease. Animal models of systemic inflammation induced by SEB and LPS were 
used to study inflammatory responses through high-density DNA microarrays.  
In an animal model of systemic inflammation induced by SEB, 134 and 
209 SEB-activated genes were identified in spleen cells and T lymphocytes, 
respectively. In T lymphocytes, 182 out of 209 activated genes were suppressed 
upon the treatment with a cell-penetrating peptide cSN50 while the same 
treatment abolished the activation of all 134 genes in the spleen. SEB-induced 
genome activation was also ablated in IκBαΔN transgenic mice. As this 
transgenic supersuppressor interferes with NFκB-mediated signal transduction, 
our data indicate that SEB-induced genome-wide transcriptional activation in T 
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lymphocytes is mediated by nuclear import of NFκB and other stress-responsive 
transcription factors. 
 
In an animal model of systemic inflammation induced by LPS in C3H/HeN 
mice, we observed upregulation of 1296 genes and downregulation of 1551 
genes in the liver. In the spleen, LPS induced upregulation of 1109 genes and 
downregulation of 402 genes. This genome-wide regulation by LPS is dependent 
on TLR-4 since C3H/HeJ mice with defective TLR-4 signaling demonstrated the 
lack of genome-wide response. Moreover, nuclear import inhibitor cSN50 blocked 
547 LPS-upregulated and 669 LPS-downregulated genes in the liver. In the 
spleen, same treatment blocked 105 LPS-upregulated and 230 LPS- 
downregulated genes. Thus, nuclear import of SRTFs plays an important role in 
the LPS-induced and TLR-4-dependent genome-wide transcriptional regulation in 
the liver and the spleen. 
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CHAPTER IV 
 
MATERIALS AND METHODS 
 
Cell lines 
  Human embryonic kidney 293T cells and MRC-5 cells were obtained from 
the American Type Culture Collection (Manassas, VA). HEK293T were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Cellgro, VA) supplemented with 
10% heat-inactivated fetal bovine serum (HI-FBS) containing no detectable LPS 
(< 6 pg/mL as determined by the manufacturer, Atlanta Biological, Norcross, GA), 
L-glutamine (2mM), penicillin (100 U/mL) and streptomycin (100 μg/mL).  MRC-5 
cells were maintained in Minimum essential medium (Eagle) supplemented with 
10% HI-FBS, L-glutamine (2mM), penicillin (100 U/mL) and streptomycin (100 
μg/mL).    All cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2.   
 
Plasmids and reagents 
The NFκB-luciferase reporter construct (κB-luc) containing five κB 
elements were a generous gift from Dean Ballard (Vanderbilt University, 
Nashville, TN). The Renilla-TK-luciferase reporter constructs (RL-TK) was 
purchased from Promega. The AU1-tagged MyD88 expressing plasmid was a gift 
from Marta Muzio (Mario Negri Institute, Italy, ref: (Muzio et al., 1997)). All 
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MyD88-TIR constructs were cloned into pcDNA3.1. An AU1-tag or Myc-tag was 
introduced at N-terminus of MyD88 or MyD88-TIR by Polymerase Chain Reaction 
(PCR). All constructs were verified by sequencing. 
 
Generation of mutants 
Pro712His mutation in TLR-4 renders the LPS response in C3H/HeJ mice 
(Poltorak et al., 1998). Similar mutation in MyD88 and MyD88-TIR[1-296(P200H) 
and 152-296(P200H)] were generated by PCR and subcloned into pcDNA3.1 
(Invitrogen, Carlsbad, CA). Alignment of members of TLR family reveals that 
three short motifs in MyD88 that are most conserved among family members: 
Box 1 (PERFDAF), Box2 (DRDVLPG) and Box 3 (SWFWTRL).   Alanine 
substitution were performed by selecting charged residues either in the 
conserved region or predicted to be on the surface. There were 3 exceptions, 
V204, Q229 and F285W286. The first two were in the region predicted to interact 
with MAL (Dunne et al., 2003), and the third was conserved hydrophobic 
residues. All mutations were made in vitro using site-directed PCR mutagenesis 
as previously described (Kunkel, 1985). Briefly, PCR was utilized with a 
supercoiled dsDNA template and two synthetic complementary oligonucleotides 
containing the desired mutation and followed by removing methylated parental 
DNA template with Dpn I. The nicked DNA containing the desired mutations was 
transformed into DH5α competent cells. Mutants were confirmed by sequencing.  
Primers used in the PCR mutagenesis are listed in Table 2.   
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Table 2. Oligonucleotides used for alanine substitution 
 
Primer    Sequence 
 
H156-S  5’-CATCGACCCCCTGGGGGCCATGCCTGAGCGTTTCG-3’ 
H156-A  5’-CGAAACGCTCAGGCATGGCCCCCAGGGGGTCGA-3’ 
ER159S  5’-CCTGGGGCATATGCCTGCCGCTTTCGATGCCTTCATCTG-3’ 
ER159-A  5’-GCACATGAAGGCATCGAAAGCGGCAGGCATATGCCCCAG-3’ 
D162S  5’-GCCTGAGCGTTTCGCTGCCTTCATCTGCTATTG-3’ 
D162A  5’-CAATAGCAGATGAAGGCAGCGAAACGCTCAGGC-3’ 
D171S  5’-GCTATTGCCCCAGCGCCATCCAGTTTGTGCAGG-3’ 
D171A  5’-CCTGCACAAACTGGATGGCGCTGGGGCAATAGC-3’ 
E177S  5’-CATCCAGTTTGTGCAGGCCATGATCCGGCAACTGG-3’ 
E177A  5’-CCAGTTGCCGGATCATGGCCTGCACAAACTGGATG-3’ 
R180S  5’-GTGCAGGAGATGATCGCGCAACTGGAACAGACAAAC-3’ 
R180A  5’-GTTTGTCTGTTCCAGTTGCGCGATCATCTCCTGCAC-3’ 
E183-S  5’-GATGATCCGGCAACTGGCACAGACAAACTATCGACTG-3’ 
E183-A  5’-CAGTCGATAGTTTGTCTGTGCCAGTTGCCGGATCATC-3’ 
R188S  5’-CTGGAACAGACACAACTTCAGTGCATAGTTTGTCTGTTCCAG-3’ 
R188A  5’-GTCAGACACACACAACTTCAGTGCATAGTTTGTCTGTTCCAG-3’ 
K190S  5’-CAGACAAACTATCGACTGGCCTTGTGTGTGTCTGACCGCG-3’ 
K190A  5’-CGCGGTCAGACACACACAAGGCCAGTCGATAGTTTGTCTG-3’ 
DRD195S  5’-CTGCCGTTGTGTGTGTCTGCCGCCGCTGTCCTGCCTGGCACCTG-3’ 
DRD195A  5’-CAGGTGCCAGGCAGGACAGCGGCGGCAGACACACACAACTTCAG-3’ 
V204S  5’-GCCTGGCACCTGTGCCTGGTCTATTGCTAG-3’ 
V204A  5’-CTAGCAATAGACCAGGCACAGGTGCCAGGC-3’ 
E210S  5’-CTGGTCTATTGCTAGTGCCCTCATCGAAAAGAGGTGCC-3’ 
E210A  5’-GGCACCTCTTTTCGATGAGGGCACTAGCAATCGACCAG-3’ 
EKS213S  5’-GCTAGTGAGCTCATCGCAGCCGCGTGCCGCCGGATGGTGGTGG-3’ 
EKS231A  5’-CCACCACCATCCGGCGGCACGCGGCTGCGATGAGCTCACTAGC-3’ 
RR218S  5’-GCTCATCGAAAAGAGGTGCGCCGCGATGGTGGTGGTTGTCTCTG-3’ 
RR218A  5’-CAGAGACAACCACCACCATCGCGGCGCACCTCTTTTCGATGA-3’ 
DD225S  5’-GATGGTGGTGGTTGTCTCTGCTGCTTACCTGCAGAGCAAGG-3’ 
DD225A  5’-CCTTGCTCTGCAGGTAAGCAGCAGAGACAACCACCACCATC-3’ 
Q229S  5’-GTTGTCTCTGATGATTACCTGGCCAGCAAGGAATGTGACTTCC-3’ 
Q229A  5’-GGAAGTCACATTCCTTGCTGGCCAGGTAATCATCAGAGACAAC-3’ 
KE231S  5’-CTGATGATTACCTGCAGAGCGCGGCATGTGACTTCCAGACC-3’ 
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 Table 2. continued 
KE231A  5’-GGTCTGGAAGTCACATGCCGCGCTCTGCAGGTAATCATCAG-3’ 
D234S  5’-GCAGAGCAAGGAATGTGCCTTCCAGACCAAATTTGC-3’ 
D234A  5’-GCAAATTTGGTCTGGAAGGCACATTCCTTGCTCTGC-3’ 
K238S  5’-GGAATGTGACTTCCAGACCGCATTTGCACTCAGCCTCTC-3’ 
K238A  5’-GAGAGGCTGAGTGCAAATGCGGTCTGGAAGTCACATTCC-3’ 
H248S  5’-CCTCTCTCCAGGTGCCGCTCAGAAGCGACTGATC-3’ 
H238A  5’-GATCAGTCGCTTCTGAGCGGCACCTGGAGAGAGG-3’ 
KR250S  5’-CTCTCCAGGTGCCCATCAGGCCGCACTGATCCCCATCAAGTAC-3’ 
KR250A  5’-GTACTTGATGGGGATCAGTGCGGCCTGATGGGCACCTGGAGAG-3’ 
K256S  5’-GAAGCGACTGATCCCCATCGCCTACAAGGCAATGAAGAAAGAG-3’ 
K256A  5’-CTCTTTCTTCATTGCCTTGTAGGCGATGGGGATCAGTCGCTTC-3’ 
K258S  5’-CGACTGATCCCCATCAAGTACGCCGCAATGAAGAAAGAGTTCC-3’ 
K258A  5’-GGAACTCTTTCTTCATTGCGGCGTACTTGATGGGGATCAGTCG-3’ 
KKE261S  5’-CATCAAGTACAAGGCAATGGCGGCAGCGTTCCCCAGCATCCTGAGG-3’ 
KKE261A  5’-CCTCAGGATGCTGGGGAACGCTGCCGCCATTGCCTTGTACTTGATG-3’ 
R269S  5’-GTTCCCCAGCATCCTGGCCTTCATCACTGTCTGCGAC-3’ 
R269A  5’-GTCGCAGACAGTGATGAAGGCCAGGATGCTGGGGAAC-3’ 
D275S  5’-GTTCATCACTGTCTGCGCCTACACCAACCCCTG-3’ 
D275A  5’-CAGGGGTTGGTGTAGGCGCAGACAGTGATGAAC-3’ 
K282S  5’-CACCAACCCCTGCACCGCATCTTGGTTCTGGACTC-3’ 
K282A  5’-AGATCCAGAACCAAGATGCGGTGCAGGGGTTGGTG-3’ 
FW285S  5’-CCTGCACCAAATCTTGGGCCGCCACTCGCCTTGCCAAGGCC-3’ 
FW285A  5’-GGCCTTGGCAAGGCGAGTGGCGGCCCAAGATTTGGTGCAGG-3’ 
R288S  5’-CAAATCTTGGTTCTGGACTGCCCTTGCCAAGGCCTTG-3’ 
R288A  5’-CAAGGCCTTGGCAAGGGCAGTCCAGAACCAAGATTTG-3’ 
K291S  5’-CTGGACTCGCCTTGCCGCCGCCTTGTCCCTGCCC-3’ 
K291A  5’-GGGCAGGGACAAGGCGGCGGCAAGGCGAGTCCAG-3’ 
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Transient transfection, reporter assay and cytokine cytometric 
beads array (CBA) 
 
Transfection of HEK 293T cells was performed with the indicated cDNAs 
by a conventional calcium phosphate method. One day before transfection, cells 
were seeded 2.5X105 /mL per 100mm plate. At 18 h after transfection, the 
culture media was replaced with fresh media, and on the following 24 h the cells 
were treated as indicated, harvested and submitted to subsequent analysis. 
When the cells were to be stimulated with IL-1β, the culture media was changed 
to media containing IL-1β (10ng/mL or indicated otherwise; Cellsciences, Canton, 
MA) and further cultured for 6 h or left untreated for the indicated period of time.  
One million MRC-5 cells were transfected with Cell Line Nucleofector Kit R 
(Amaxa, Gaithersburg, MD) program U23 following manufacture’s protocol. At 8 
h after transfection, cells were washed with HBSS and fresh media added. Cells 
were stimulated with IL-1β for 6h next day, and culture media were collected 
and analyzed for production of cytokines and chemokines.   
SN50 which inhibit nuclear translocation of NFκB and other SRTFs has 
been described elsewhere (Hawiger, 1999; Lin et al., 1995). SN50 peptide was 
synthesized, purified and prepared as described before (Yan Liu et al., 2000). 
One million MRC-5 cells in 6-well plates were seeded and treated with diluent or 
SN50(100 μM) in HBSS for 30 minutes before and followed by IL-1 10ng/mL 
treatment for 6 h. Culture media were collected and IL-1β-stimulated 
cytokines/chemokines production of MRC-5 cells was analyzed by Human 
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Inflammation cytometric beads array Kit (BD Biosciences, San Diego, CA) 
according to manufacture’s protocol.  
For reporter gene activity assay, HEK 293T cells were transfected with the 
NFKB-dependent luciferase reporter gene (NFKB-Luc) together with pRL-TK 
(Promega). The NFκB-Luc vector contains firefly luciferase gene controlled by 
five reiterated κB sites. The pRL-TK Vector, as an internal control reporter, 
contains a renilla luciferase gene under the herpes simplex virus thymidine 
kinase (HSV-TK) promoter. HEK 293T cells were harvested and submitted to 
subsequent Dual-luciferase assay according to manufacture’s protocol (Promega 
technical manual #TM040). 
 
Immunoblotting and indirect immunofluorescence 
To check the protein expression after transient transfection, 293T cells 
were seeded (2.5X105 mL-1) onto 100-mm dishes 24 h prior to transfection with 
combinations of plasmids (20 µg total) as indicated using calcium phosphate 
method. 36 h post-transfection cells were washed by the addition of 5 mL of ice-
cold phosphate-buffered saline. Cells were lysed on ice for 10 min in lysis buffer 
containing 150 mM NaCl, 2 mM EDTA, 10% glycerol, 0.1% NP-40, 0.2 mM  
phenylmethylsulfonyl fluoride, 0.2 mM Na3VO4, and 1 µg of leupeptin mL–1. 50 µg 
of cell lysate was separated by SDS-PAGE, and then analyzed by immunoblotting.  
Monoclonal antibodies against the epitope tags myc and AU1 were obtained from 
Covance(Berkeley, CA). For indirect immunofluorescence —105  transfected HEK 
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293T cells were cytocentrifuged  onto glass slide and fixed with 3.5% 
paraformaldehyde. After washing with PBS, cells were permeablized with 0.25% 
Triton X-100 for 10 min and then probed with anti-AU1 antibody followed by 
Rhodamine Red-X labeled goat anti mouse IgG antibody (Jackson 
ImmunoResearch Lab, West Grove, PA) as described (Lin et al., 1995). Slides 
with stained cells were mounted in Poly/Mount (Polysciences, Warrington, PA) 
and analyzed in an Olympus fluorescence microscope using a  X 100 oil 
immersion lens. 
 
Co-immunoprecipitation 
HEK 293T cells were plated 5X106per 100 mm plate. 24h later, cells were 
transfected with 10mg of myc-MyD88 and 10 mg of AU1-TIR or TIR mutants 
using Calcium phosphate method. Fresh media was added 18 h later and 
incubated for 24h. Cells were washed with PBS and resuspended in 400 µL 
hypotonic gentle lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 10 mM EDTA, 
0.5% Triton-X100, 1 mM PMSF, 1 µM aprotinin, 1 µM leupeptin). 200 mg of 
lysate was incubated with 10 µg anti-AU1(Covance, Berkeley, CA) at 4°C 
overnight. 10 µl Protein G Sepharose 4 fast flow slurry (Amersham) were added 
and incubated for 3 h at 4°C. Beads were washed 8 times with 0.5 mL of wash 
buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM EDTA, 0.5% Triton-X100, 1 
mM PMSF, 1 µM aprotinin, 1 µM leupeptin). Beads were resuspended in 2X 
Laemmli buffer. The samples were fractionated on 15% SDS-PAGE, transferred 
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to a PVDF membrane and subjected to immunoblotting analysis with specific 
antibody (anti-myc, Covance; Berkeley, CA). As a control, 50 µg of total cell 
lysate was applied to immunoblotting with same antibody. As a second control, 
counter immunoprecipitations were also performed. 
 
Modeling studies 
The 3-dimensional models of MyD88 and IL1RAcP TIR domain structure 
were established by comparative modeling computation using Swiss-Model 
homology-modeling server(Guex and Peitsch, 1997; Schwede et al., 2003). 
Within known 3-dimensional structures of TIR domain from highly homologous 
TLR family members, there are at least 7 PDB records (Tao et al., 2002; Xu et al., 
2000).  TIR domain of human TLR-2 with an alignment identity 31% and over 
50% of similarity comparing with MyD88 was used for MyD88 TIR domain 
comparative modeling (PDB file of 1o77). TIR domain of human TLR1 with an 
identity 33% compare with MyD88 was used for comparative modeling of 
IL1RAcP(PDB file of 1fyvA). 
 
Peptide synthesis 
The cell-permeable peptide cSN50 was synthesized, purified, filter-
sterilized, and analyzed as described elsewhere(Torgerson et al., 1998; Yan Liu 
et al., 2000).  The cSN50 peptide carries a nuclear localization sequence (NLS) 
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derived from p50/NFκB1 and membrane-translocating motif (MTM) which leads 
the functional cargo into across cell membrane.  
 
Delivery of cell-penetrating peptides in vivo 
C57BL/6 mice were purchased from the Jackson Laboratory.  Transgenic 
C57BL/6 mice expressing IκBαΔN in T cell lineage were engineered as previously 
described(Boothby et al., 1997; Liu et al., 2004b).  Unlike wild type IκBα, the 
IκBαΔN mutant protein is resistant to degradation and functions as constitutive 
repressor of NFκB (Boothby et al., 1997; Liu et al., 2004b).  All of the mice were 
female (8 - 12 weeks old) with an average weight of 20 grams.  Unless noted 
otherwise, mice were injected intravenously with 150 μg of SEB (Toxin 
Technology).  SEB has been purified with additional procedure by the 
manufacturer so that it contains less than 1 endotoxin unit (EU) of LPS per mg.  
Cell-permeable peptide cSN50 (0.7 mg) was dissolved in pyrogen-free water 
containing 5% DMSO. Animal handling and experimental procedures were 
performed in accordance with the American Association of Accreditation of 
Laboratory Animal Care Guidelines and were approved by the Institutional Animal 
Care Committee. 
 
Measurement of cytokine/chemokine expression 
Blood samples were collected from the saphenous vein in heparinized 
tubes before (30 mins.) and after (1, 6, and 24 hours) SEB challenge.  Plasma 
116
levels of TNF-α, IFN-γ, and IL-2 were measured by cytometric bead array (CBA) 
according to the manufacturer's protocol as described previously (Liu et al., 
2004b).  
 
Isolation of T lymphocytes from the spleen 
Murine lymphocytes were isolated from the spleens of wild type C57BL/6 
mice and transgenic C57BL/6 mice that express IκBαΔN (inhibitor of NFκB nuclear 
translocation) as previously described (Yan Liu et al., 2000).  By depletion of 
MHC Class II expressing cells, the intact T cells enriched from spleen contained 
83-90% of CD3 positive cells. 
 
RNA extraction and reverse transcriptase reaction 
Total RNA was extracted from mouse tissue and enriched T cells using 
Trizol Reagent (Invitrogen) following the manufacturer’s instructions with slight 
modification to eliminate the contamination of polysaccharides and proteoglycons. 
The RNA samples were DNase-treated (Promega) and treated with 
phenol/chloroform two times to remove DNase.  The RNA samples were then 
cleaned up using RNeasy kit (Qiagen). RNA isolated from T cells isolated from a 
group of C57BL/6 or I B.DN mice were pooled to get sufficient amount and 
analyzed as one sample.  RNA from spleen isolated from each mouse is not 
pooled. RNA was quantified by spectrophotometry and its integrity was assured 
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by analysis using an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, 
CA).  
 
Construction of microarray containing 22k genes 
Microarrays containing 22,172 cloned genes from the National Institute on 
Aging 15k cDNA clone set, mouse sequence-verified clones from Research 
Genetics and several control genes were generated by the Vanderbilt Microarray 
Shared Resource. Full gene lists and protocols are available at 
http://array.mc.vanderbilt.edu.  Briefly, all cDNA clones were amplified and 
verified by gel electrophoresis.  The dried PCR products were then resuspended 
in 40 μl VMSR buffer A [Vanderbilt Microarray Shared Resource, Nashville, TN] 
resulting in an average concentration of 400 – 700 μg/ml per product.  The PCR 
products were then transposed to 384 well plates and robotically arrayed using a 
BioRobotics MicroGrid II microarray printing robot (Apogent Discoveries, Hudson, 
NH) onto amine-coated  glass slides (TeleChem International, Sunnyvale, CA).  
The microarrays were then crosslinked using  80mjoules of ultraviolet energy 
(Stratagene Stratalinker, LaJolla, CA).  Following crosslinking, the arrays were 
baked for two hours at 70°C in a standard oven and stored under low humidity 
conditions until use.    
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Target labeling and coupling 
All RNA Preps were run on an Agilent 2100 Bioanalyzer to assess RNA 
integrity. Those samples meeting minimum requirements of RIN value of 7.0 and 
greater were used to generate cDNA targets for hybridization to spotted arrays in 
the following manner: 5-10μg of total RNA from each sample was reverse 
transcribed at 42 °C using 400 units Superscript II (Invitrogen) in the presence 
of 6ug anchored oligo dT and an Amino-allyl tagged dUTP (Sigma, A0410).  
Additionally, RNA Spike- In controls (Ambion, cat#1780) were added at 
concentrations ranging from 0 – 200pg per spike per reverse transcriptase 
reaction.  These 8 control spike-ins hybridize to the Ambion control spots on 
VMSR arrays. Final concentrations of dNTP's in the reaction were 200μM dA, dG, 
dC, 51μM dT, and 149μM AAdUTP (Sigma A 0410).  cDNA targets generated 
were incubated with NaOH to hydrolyze any remaining total RNA, then 
neutralized with HCl, and cleaned over Qiaquick columns (Qiagen, 28106).  The 
targets were dried to completion and then coupled to ester-linked Cy5 and Cy3 
dyes (Amersham PA23001 Cy3, and PA25001 Cy5) in 0.1M Sodium Bicarbonate 
(pH. 9.0) for 60 minutes in a 6μl volume to facilitate the coupling reaction. After 
quenching of unbound dye with 4M Hydroxylamine (Aldrich 43,136-2) Cy3 and 
Cy5 pairs were combined and the target pairs were cleaned up over Qiaquick 
columns again (Qiagen, 28106) and then dried to completion in a speed-vac. The 
targets were then resuspended in 50μl of MWG Hyb Buffer (Ocimum Biosolutions, 
cat#1180-200000) and 1 μg of Poly A RNA (Sigma, P9403) was added to each 
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target. The targets were heat denatured and then hybridized 16 hours at 42°C 
on a Maui Hyb Station (BioMicro Systems, Inc.).  Following post hybridization 
washes all arrays were scanned on an AXON 4000b scanner.  
 
Data analysis of microarray 
Microarrays were scanned and the raw data was generated by the 
accompanying software, GenePix 4.1.  Raw data were then analyzed using 
GeneTraffic 2.6 by Iobion Informatics, LLC.  All 20,996 spots were first filtered 
and removed from analysis if the following criteria were not met: (i) Cy5 signal to 
background intensity ratio less than 2; (ii) Cy3 signal to background intensity 
ratio less than 2; (iii) Cy5 signal less than 200; (iv) Cy3 signal less than 200. 
The arrays were performed in at least triplicate for each group (SEB 
Spleen, SEB+cSN50, SEB-T cell, SEB+cSN50 T cell, SEB-Transgenic, Trans-no 
SEB, all at 24hr).  Between three and six RNA samples were collected from 
experimental time point (SEB Spleen, SEB+cSN50, SEB-T cell, SEB+cSN50 T cell, 
SEB-Transgenic, Trans-no SEB, all at 24hr) and matched control samples were 
labeled with Cy3 and Cy5 dyes. Labeling of these RNA samples yielded equal 
amounts of labeled probes indicating the initial RNA quantity was equal and 
there was no artifact introduced during the labeling procedure. Therefore, 
possibility of general decline in the abundance of transcript can be excluded. The 
possibility of introduction of variation due to sample-to-sample variation was 
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reduced because of the number of replicate RNA samples.  The average 
statistically significant intensities were obtained by using GeneTraffic software.  
Data was normalized using the Lowess sub-grid method.  Lists of features 
with a fold change of greater than 2.0 fold and a coefficient of variance of less 
than 30% (across multiple arrays) that repeated expression in the hybridizations 
under the same conditions were generated for each condition.  These gene lists 
were then compared to each other in order to identify genes with interesting 
expression profiles across each condition.   
In addition to GeneTraffic, GeneSpring (Silicon Genetics) was also used to 
illustrate the hierarchical correlation between the genes. This data analysis 
software uses numerical expression data from microarray results and illustrates 
the possible correlation between the expression profiles amongst the genes 
based on their expression levels. We analyzed the genes suppressed and 
expressed in whole spleen cells treated with SEB when cSN50 was added at 
24hrs, and studied their expression profile by clustering. Similar analysis was also 
performed on the changing expression of the genes in T cells when the cSN50 
peptide was added at 24 hrs. We also studied the cluster analysis of the genes 
that are commonly expressed among the whole spleen cells and T cells in 
response to the addition of cSN50 at 24 hrs.     
 
 
 
121
Affymetrix-based microarray analysis 
Affymetrix mouse gene chip platform is provided by the Vanderbilt 
Microarray Shared Resource (VMSR). This high-density oligonucleotide chip 
contains over 39,000 transcripts, within which 34,000 are annotated as well-
defined genes.  Following hybridization, arrays are washed and scanned 
according to Affymetrix protocols (Affymetrix Inc, Santa Clara, CA).  All 
instrument control and initial data analysis is performed using GCOS.  Additional 
analysis employing alternative probe-level methods is performed in GeneTraffic 
(Iobion Informatics). Following data collection, all arrays will be analyzed using 
both the MAS5.0 algorithm (default Affymetrix approach, www.affymetrix.com) 
as well as the Robust Multichip Analysis (RMA) approach. Several statistical 
methods for the determination of differential expression or classification are 
available in the GeneTraffic package or other software packages (GeneSpring, 
Bioconductor, Array Analyzer). Genes identified as significantly differentially 
expressed are annotated with pathway, chromosomal and gene ontology 
information, providing a functional and organizational view of the data to 
potentially identify biologically relevant patterns. 
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